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ABSTRACT 
 
Cancer is becoming the leading cause of deaths in the world. As 90% of all deaths from 
cancer are caused by metastasis, discovery of the mechanisms behind cancer cell invasion 
and metastasis is of utmost importance. Only new effective therapies targeting cancer 
progression can reduce cancer mortality rates. 
 
The aim of this study was to identify molecules that are relevant for tumor cell invasion and 
spreading in fibrosarcomas and melanomas, and to analyze their potential for cancer 
biomarkers or therapeutic targets. First, the gene expression changes of normal cells and 
transformed cells showing high invasiveness, S-adenosylmethionine decarboxylase 
(AdoMetDC)-transfected murine fibroblasts and human melanoma cells, were studied by 
microarray analyses. The function of the identified candidate molecules were then studied in 
detail in these cell lines. Finally, the physiological relevance of the identified changes was 
studied by immunohistochemical analyses of human sarcoma and melanoma specimens or by 
a mouse xenograft model. 
 
In fibrosarcoma cells, the most remarkable change detected was a dramatic up-regulation of 
the actin-sequestering molecule thymosin β4 (Tβ4), which was shown to be important for the 
transformed phenotype of the AdoMetDC-transfected cells (Amdc-s and -as). A sponge toxin 
latrunculin A, inhibiting the binding of Tβ4 to actin, was found to selectively inhibit the 
migration and invasion of these cells. Further, Amdc-s-induced mouse tumors and human 
high-grade sarcomas were found to show intense Tβ4 immunostaining. In addition to Tβ4, 
integrin subunits α6 and β7 (Itgα6 and Itgβ7) were found to be up-regulated in Amdc-s and -
as cells. Itgα6 was shown to dimerize mainly with Itgβ1 in Amdc-s. Inhibition of Itgα6 or 
Itgβ1 function with neutralizing antibodies fully blocked the invasiveness of Amdc-s cells, 
and importantly also human HT-1080 fibrosarcoma cells, in three-dimensional (3D)-Matrigel 
mimicking tumor extracellular matrix (ECM). By immunohistochemical analyses, strong 
staining for ITGα6 was detected in human high-grade fibrosarcomas and other sarcomas, 
especially at the invasion fronts of the tumors. 
 
In the studied melanoma cell lines, the expression levels of the adhesion-related ECM 
proteins tenascin-C (TN-C), fibronectin (FN), and transforming growth factor beta-induced 
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(TGFBI) were found to be highly up-regulated. By immunohistochemistry, intense TN-C and 
FN staining was detected in invasive and metastatic melanoma tumors, showing co-
localization (together with procollagen-I) in tubular meshworks and channels around the 
invading melanoma cells. In vitro, TN-C and FN were further found to directly stimulate the 
migration of melanoma cells in 3D-collagen-I matrix. The third candidate protein, TGFBI, 
was found to be an anti-adhesive molecule for melanoma cells, and knockdown of its 
expression in metastatic melanoma cells (TGFBI-KD cells) led to dramatically impaired 
tumor growth in immunocompromized mice. Interestingly, the control tumors showed intense 
TGFBI immunostaining in the invasion fronts, showing partial co-localization with the 
fibrillar FN staining, whereas the small TGFBI-KD cell-induced tumors displayed 
amorphous, non-fibrillar FN staining. These data suggest an important role for TGFBI in FN 
fibrillogenesis and melanoma progression. 
 
In conclusion, we have identified several invasion-related molecules, which show potential 
for cancer diagnostic or prognostic markers, or therapeutic targets. Based on our previous and 
present fibrosarcoma studies, we propose the possibility of using ITGα6 antagonists 
(affecting tumor cell adhesion) in combination with Tβ4 inhibitors (affecting tumor cell 
migration) and cathepsin L inhibitors (affecting the degradation of basement membrane and 
ECM proteins) for the treatment of fibrosarcomas and other tumors overexpressing these 
molecules. With melanoma cells, in turn, we point to the importance of three secreted ECM 
proteins, TN-C, FN, and TGFBI, in melanoma progression. Of these, especially the potential 
of TN-C as a prognostic melanoma biomarker and TGFBI as a promising therapeutic target 
molecule are clearly worth additional studies. 
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AdoMetDC S-adenosylmethionine decarboxylase 
BM  basement membrane 
BSA  bovine serum albumin 
CAF  cancer-associated fibroblast 
cFN  cellular fibronectin 
CM  conditioned media 
COL  collagen 
CSF-1  colony stimulating factor-1 
DAPI  4’,6-diamidino-2-phenylindole 
ECM  extracellular matrix 
EGF  epidermal growth factor 
EMT  epithelial to mesenchymal transition 
FAK  focal adhesion kinase 
FAS  fasciclin 
FBS  fetal bovine serum 
FGF  fibroblast growth factor 
FITC  fluorescein isothiocyanate 
FN  fibronectin 
Gapdh  glyceraldehyde-3-phosphate dehydrogenase 
HGF  hepatocyte growth factor 
IHC  immunohistochemistry 
IL  interleukin 
Itg/ITG integrin (mouse/human) 
KD  knockdown 
LAP  latency-associated peptide 
LAT-A latrunculin A 
LN  laminin 
LTBP  latent TGF-β-binding protein 
MMP  matrix metalloproteinase 
ODC  ornithine decarboxylase 
pFN  plasma fibronectin 
PDGF  platelet derived growth factor 
POSTN periostin 
RGP  radial growth phase 
RT-PCR reverse transcription polymerase chain reaction 
shRNA short hairpin RNA 
siRNA  small interfering RNA 
Tβ4  thymosin β4 
Tβ10  thymosin β10 
TIMP  tissue inhibitor of metalloproteinases 
TGF-β  transforming growth factor β 
TGFBI  transforming growth factor beta-induced 
TLN  talin 
TN  tenascin 
TNF-α  tumor necrosis factor α 
TRITC  tetramethyl rhodamine isothiocyanate 
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UV  ultraviolet 
VEGF  vascular endothelial growth factor 
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 12 
 
INTRODUCTION 
 
Worldwide cancer incidence and the number of cancer-related deaths are rising all the time. 
In Finland, there are currently more than 205,000 persons with cancer diagnosed at some 
point in their life (some of them are cured), and over 10,000 persons die of cancer every year 
(Finnish Cancer Registry 2009). The corresponding worldwide numbers are as high as 25 
million and over 7 million, respectively (Ferlay et al. 2004). Regardless of the improved 
cancer diagnostics and treatments leading to decreasing age-adjusted cancer mortality rates, 
the highly increasing incidence rate, especially in the developing countries, results in a steady 
rise in the number of cancer victims. In Finland, it has been estimated that by 2020, there will 
be annually about 25-30% more new cancer cases and 10-20% more cancer deaths (Finnish 
Cancer Registry 2009). As the main cause (90%) for cancer-related deaths is the 
dissemination of the cancer, metastasis (Gupta and Massagué 2006), discovery of the 
molecules and mechanisms relevant for cancer cell invasion and metastasis is highly 
important. New, more effective therapies targeting cancer progression are needed to stop the 
rise in worldwide cancer mortality. 
 
In this study, we investigated mouse fibroblasts transformed by the polyamine biosynthetic 
enzyme S-adenosylmethionine decarboxylase (AdoMetDC), along with human fibrosarcoma 
specimens, human melanoma cells, and human melanoma specimens. The polyamines 
spermidine and spermine, and their diamine precursor putrescine, are small polycationic 
molecules essential for normal cell growth (for a review see Pegg 1988; Pegg 2009). 
Polyamines function by binding to various anions in the cells, including DNA, RNA, and 
phospholipids, thereby stabilizing these molecules. Further, polyamines are known to 
influence the transcription of many genes, to regulate ion channels, and to affect the activity 
of many enzymes. AdoMetDC and ornithine decarboxylase (ODC) are the two key regulatory 
enzymes of the tightly controlled biosynthetic pathway of polyamines. ODC catalyzes the 
first step, synthesis of putrescine, and AdoMetDC catalyses the formation of decarboxylated 
S-adenosylmethionine, which is needed in the conversion of putrescine to spermidine and 
spermine. As an indication of the need for tightly controlled polyamine biosynthesis to 
control cell growth, aberrant polyamine metabolism is known to be related to carcinogenesis 
(Pegg 1988 and the references therein). Interestingly, overexpression of both ODC (Auvinen 
et al. 1992; Moshier et al. 1993; Shantz and Pegg 1994) and AdoMetDC (Paasinen-Sohns et 
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al. 2000), by themselves, has been shown to induce tumorigenic cell transformation of rodent 
cells. In addition, also blockage of AdoMetDC expression has been found to induce cell 
transformation (Paasinen-Sohns et al. 2000). The AdoMetDC-transformed mouse fibroblasts, 
transfected in either sense (Amdc-s) or antisense orientation (Amdc-as), form highly invasive 
fibrosarcomas in nude mice, rapidly penetrating from the subcutaneous injection site in the 
flanks into the peritoneal cavity. In addition, these cells are in vitro even more invasive than 
the c-Ha-rasVal12-oncogene-transformed murine fibroblasts (E4), human HT-1080 
fibrosarcoma cells, or human MDA-MB-231 breast cancer cells (Ravanko et al. 2004; 
Paasinen-Sohns et al. 2011). The aggressive Amdc-s and Amdc-as cells thus offer a good 
model to study the molecules relevant for the invasion and dissemination of fibrosarcomas. 
 
Melanoma is a malignant tumor originating from the melanocytes, the cells responsible for 
the production of the dark pigment melanin (reviewed in Villanueva and Herlyn 2009). 
Melanoma is one of the less common types of skin cancer, but due to its high tendency to 
invade and metastasize, it causes the great majority of the skin cancer-related deaths (Kumar 
et al. 2007). Further, melanoma affects relatively young people. As the worldwide incidence 
of melanoma is rising and no effective treatment currently exists for the treatment of 
disseminated melanoma (Villanueva and Herlyn 2009; Garbe et al. 2011), it is extremely 
important to solve the mechanisms of melanoma cell invasion and dissemination. 
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REVIEW OF THE LITERATURE 
 
1. CANCER DEVELOPMENT 
Malignant tumors arise from normal cells, any cells in the body, which escape the control of 
normal growth. According to the common view, six hallmark capabilities are required for 
malignant growth: self-sufficiency for external growth signals, insensitivity to negative 
growth signals, resistance to programmed cell death (apoptosis), limitless replicative 
potential, sustained formation of new blood vessels (angiogenesis), and acquisition of tissue 
invasiveness (Hanahan and Weinberg 2000). However, clinically the most important of these 
capabilities is tissue invasiveness, which, in contrast to the other capabilities, is only found in 
malignant tumors and not in benign ones (Lazebnik 2010). Cancer development thus is a 
multistep process that usually takes a time span of decades. Normal tissues may first develop 
hyperplasia, just by uncontrolled proliferation, and form then benign tumors, which may 
gradually develop dysplasia, showing also cytological abnormality and architectural 
distortion. Finally these benign tumors may develop into malignant tumors able to invade the 
adjacent tissues (for a review see Weinberg 2007). The initiating events in the pre-malignant 
cells are mainly gene mutations and deletions leading to activation of oncogenes and 
inactivation of tumor suppressor genes, but at the later stages of cancer development, the 
changes are mostly seen in gene expression (Sager 1997). In this thesis I will concentrate on 
these gene expression changes in two highly aggressive malignancies. 
 
Fibrosarcoma, the first target disease, is a non-epithelial cancer type arising from fibroblasts, 
a cell type originating from the mesoderm of the embryo. As compared to many more 
common fibroblastic proliferations, fibrosarcomas are highly malignant neoplasms often 
harboring the ability to recur locally or to invade and spread to distant organs (metastasize) 
(Kumar et al. 2007). Malignant melanoma, the second target, is a non-epithelial cancer type 
as well, evolving from melanocytes, the pigmented cells of the skin and the retina of the eye. 
Melanocytes, in turn, arise from an ectodermal embryonic structure termed the neural crest 
and are distributed as single cells within the basal layer of epidermis (Satyamoorthy and 
Herlyn 2002).  The role of melanocytes in the skin is to produce melanin-pigment upon UV-
light induction, which protects the skin from UV-light-induced DNA damage. Melanoma is 
less common skin cancer than basal and squamous cell carcinomas, nevertheless it is far more 
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deadly than those two main skin cancer types (Kumar et al. 2007). Indeed, melanomas often 
have a high and unpredictable tendency to metastasize. The phases of melanoma 
development are relatively well known (nicely reviewed in Villanueva and Herlyn 2009) and 
are depicted in Figure 1. The way towards melanoma starts with initial proliferation of 
melanocytes, leading to benign nevi. Some of the nevus cells may then continue anomalous 
growth and become dysplastic, but still stay in the epidermis. Then, again some of the nevus 
cells may acquire the ability to invade the surrounding epidermis and are said to be at the 
radial growth phase (RGP). Later in melanoma progression, some of the tumor cells further 
acquire the ability to invade vertically deep into the dermis (vertical growth phase, VGP), 
and, finally, to metastasize into the regional lymph nodes and distal organs (metastatic 
phase), and kill the patient. Recently, cancer stem-like cells, already defined in various 
human and mouse tumors, have also been identified in melanoma tumors (Zabierowski and 
Herlyn 2008). Thus, in addition to the classical view of melanoma development, melanoma 
tumors may also arise from these interesting cells, possessing self-renewal capacity, 
differentiation potential, and, most importantly, high tumorigenicity. 
 
 
 
 
Figure 1. A schematic representation of the classical stages of melanoma development and 
progression. Environmental factors such as UV-light and the tumor microenvironment alterations are 
influencing these processes. RGP and VGP stand for radial and vertical growth phases, respectively. 
Modified from Villanueva and Herlyn 2009. 
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A locally growing tumor is usually not a life-threatening condition. The process of metastasis 
makes it fatal. Indeed, metastasis accounts for 90% of human cancer deaths (Gupta and 
Massagué 2006). The process of metastasis has been viewed as a series of events including 
dissociation of cancer cells from the primary tumor, local invasion, intravasation into blood 
or lymphatic vessels, survival in these channels, extravasation from the vessels, and 
colonization at a distant site (for a review see Gupta and Massagué 2006; Weinberg 2007; 
Nguyen et al. 2009). To achieve these successes, cancer cells have to become able to move 
and to degrade the surrounding tissue matrix (unless exploiting amoeboid migration). To 
obtain these abilities, cancer cells reactivate gene expression programs related to embryonic 
development and tissue remodeling like wound healing. Indeed, tumors have been depicted as 
“wounds that do not heal” (Dvorak 1986). In this thesis, I will concentrate on the process of 
local invasion, a prerequisite for metastasis. 
 
 
 
2. TUMOR MICROENVIRONMENT 
Malignant tumor cells do not exist alone, but are surrounded by multiple types of stromal 
cells, as well as various proteins of the extracellular matrix (ECM) (see Fig. 2). Growing 
number of studies emphasize the importance of the tumor microenvironment in cancer 
progression. Under normal conditions, the cellular microenvironment is able to suppress 
malignant cell growth, but the tumor-modified microenvironment, developing as a product of 
continuing crosstalk between tumor cells and the surrounding stromal cells (paracrine 
signaling), has been shown to permit or even promote tumor progression. The modifications 
taking place in the tumor microenvironment include for instance modification of ECM 
composition (degradation of the existing molecules by proteases, and synthesis and 
deposition of new ECM components), activation of stromal fibroblasts, and the recruitment of 
immune and inflammatory cells into the area. Instead of cancer cells alone, cancer research 
has, therefore, started to increasingly concentrate on the tumor tissue as a whole. 
 
 
2.1 Stromal cells and surrounding epithelia 
The tumor may contain, in addition to the tumor cells, various types of stromal cells, 
including fibroblasts, endothelial cells, pericytes, smooth muscle cells, and various 
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leukocytes (Satyamoorthy and Herlyn 2002; Coussens and Werb 2002; Lorusso and Rüegg 
2008). In addition, surrounding normal tissue components such as epidermal keratinocytes in 
melanoma interact with tumor cells. In many tumors the number of these ancillary cells 
greatly exceeds that of the neoplastic cells. 
 
 
 
 
 
 
Figure 2. The tumor microenvironment contains multiple cell types, which crosstalk by soluble 
mediators, growth factors, cytokines, and chemokines, embedded in the extracellular matrix. 
 
 
2.1.1 Keratinocytes 
Epidermal keratinocytes are important for the homeostasis of normal skin (Satyamoorthy and 
Herlyn 2002). Keratinocytes keep the proliferation of melanocytes under control via 
homotypic cell-adhesion mediated by E-cadherin (see the section 3.1.1) expressed at the 
surface of both the cell types. Thus, in normal skin, melanocytes do not divide. Malignant 
melanoma cells, in turn, often show down-regulated expression of E-cadherin (Hoek 2007) 
and hence escape the control of keratinocytes. In addition to E-cadherin-mediated 
interactions, epidermal keratinocytes regulate the phenotype of neighboring melanocytes via 
paracrine signaling utilizing growths factors and cytokines such as interleukin-1β (IL-1β), 
tumor necrosis factor α (TNF-α), and epidermal growth factor (EGF) (Fukunaga-Kalabis et 
al. 2008). 
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2.1.2 Fibroblasts 
Cancer-associated fibroblasts (CAFs) (reviewed in Kalluri and Zeisberg 2006; Räsänen and 
Vaheri 2010) appear to be highly important for tumor growth and progression. Fibroblasts, 
the most abundant cell type in connective tissues, are in normal conditions in an inactive, 
quiescent state, but become activated to myofibroblasts (which start to express α-smooth 
muscle actin, hence the name) in wound healing and fibrosis, and start to synthesize ECM 
components such as collagens. Similarly, in the stroma of tumors, “wounds that do not heal”, 
some of the fibroblasts become “activated CAFs” that start to secrete ECM components and 
ECM modifying proteases, including matrix metalloproteinases (MMPs) and urokinase-type 
plasminogen activator (uPA). In contrast to wound myofibroblasts, which are removed by 
apoptosis after the wound is healed, activated CAFs remain in the tumor-modified 
microenvironment (Räsänen and Vaheri 2010). In addition to ECM remodeling, the CAFs 
crosstalk with tumor cells by producing various growth factor molecules such as hepatocyte 
growth factor (HGF) and transforming growth factor β (TGF-β), and regulate the 
inflammatory response by secreting cytokines and chemokines. Further, CAFs stimulate 
angiogenesis by secreting factors like vascular endothelial growth factor (VEGF) that activate 
endothelial cells and pericytes. Importantly, CAFs may also stimulate the process of 
epithelial to mesenchymal transition (EMT; see 3.1.1), an important determinant of epithelial 
cancer progression (Kalluri and Zeisberg 2006). 
 
 As an example of the complex crosstalk between tumor cells and fibroblasts, melanoma cells 
are known to stimulate the proliferation of stromal fibroblasts by producing basic fibroblast 
growth factor (bFGF), which is also an important autocrine growth factor for melanoma cells 
themselves, and platelet derived growth factor (PDGF) targeting only stromal cells 
(Satyamoorthy and Herlyn 2001). PDGF is known to induce the proliferation of fibroblasts, 
but not their activation (Kalluri and Zeisberg 2006). Further, melanoma cells produce TGF-
β1, which is able to activate stromal fibroblasts to synthesize ECM components, such as 
collagens, fibronectin, and tenascins, leading to increased melanoma cell survival and 
metastasis formation (Berking et al. 2001). Notably, TGF-β is also known to mediate 
fibroblast activation during wound healing and fibrosis (Kalluri and Zeisberg 2006). 
Activated fibroblasts, in turn, reciprocally stimulate melanoma cells by producing e.g. 
insulin-like growth factor-1, HGF, bFGF, and TGF-β (Satyamoorthy and Herlyn 2001; Lee 
and Herlyn 2007; Melnikova and Bar-Eli 2009). However, the involvement of fibroblasts in 
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melanoma progression seems to be stage-dependent, as co-cultured fibroblasts have been 
shown to enhance the growth of metastatic melanoma cells, but to repress that of RGP 
melanoma (Lee and Herlyn 2007). 
 
 
2.1.3 Endothelial cells 
To be able to grow beyond 1 mm in diameter, the developing tumor needs a blood supply to 
deliver oxygen and nutrients. In order to stimulate the process of angiogenesis, normally 
occurring during embryonic development, wound healing, and tissue regeneration, tumor 
cells and surrounding stromal cells (like CAFs and inflammatory cells, see below) produce 
soluble pro-inflammatory and pro-angiogenic cytokines, including VEGF, TNF-α, and IL-8, 
which stimulate the endothelial cells of a nearby blood vessel to proliferate and migrate 
towards the tumor (Brooks et al. 2010). These migrated endothelial cells then form a vascular 
network, which is less organized and worse functioning than normal vasculature, but still 
nourishes the growing tumor and provides a route for the hematogeneous spreading of the 
tumor. In addition, tumor cells use similar process of lymphangiogenesis (exploiting VEGF-
C) to attract endothelial cells of the lymphatic vessels (Alitalo et al. 2005). Besides 
stimulation of endothelial cell proliferation and migration, tumor and stromal cell-secreted 
VEGF induces separation of endothelial cells in venules, thereby causing normal blood 
vessels to leak plasma proteins, like fibrinogen and plasminogen (Dvorak 1986). Some 
evidence also exists for reciprocal signaling, where lymphatic endothelial cells actively 
attract tumor cells by secreting chemokines like CCL21 (Alitalo et al. 2005). 
 
 
2.1.4 Inflammatory and immune cells 
Tumor tissues are often infiltrated by inflammatory and immune cells. Traditionally these 
cells have been related to host defense against the tumor, but nowadays the tumor cells and 
the infiltrating inflammatory and immune cells are also known to have reciprocal interactions 
between each other, promoting tumor progression (reviewed in Coussens and Werb 2002; 
Lorusso and Rüegg 2008; Qian and Pollard 2010). Initially, tumor cells and the surrounding 
stromal cells release growth factors and cytokines that are chemoattractive for leukocytes, 
including colony stimulating factor-1 (CSF-1) and monocyte chemotactic protein, thereby 
attracting leukocytes into the area and stimulating them to differentiate. In addition, for 
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instance melanoma cells use these chemokines for autocrine stimulation of their own 
proliferation (Coussens and Werb 2002). The recruited leukocytes include e.g. neutrophils, 
eosinophils, basophils, dendritic cells, monocytes/macrophages, natural killer cells, and 
lymphocytes (Coussens and Werb 2002), but macrophages are thought to be the most 
important in respect to tumor progression (Qian and Pollard 2010). Indeed, over 80% of 
studies report a correlation between macrophage density and poor patient prognosis (Qian 
and Pollard 2010). 
 
As the signaling is bidirectional, the activated leukocytes, in turn, secrete cytokines (like 
TGF-β and TNF-α) that influence tumor cells and the surrounding stromal cells such as 
fibroblasts, and recruit additional inflammatory cells (Coussens and Werb 2002). 
Importantly, TNF-α and IL-1α secreted by the activated macrophages may stimulate 
melanoma cells to produce angiogenic IL-8 and VEGF (Melnikova and Bar-Eli 2009). 
Further, macrophages stimulated by the tumor-secreted CSF-1 in turn produce EGF, which 
reciprocally activates migration of the tumor cells (Qian and Pollard 2010). The tumor-
associated macrophages produce many proteases, including MMPs and serine proteases such 
as uPA, facilitating tumor invasion. These proteases make angiogenic growth factors (like 
VEGF) bioavailable by releasing ECM-bound molecules, but more importantly, macrophages 
themselves produce VEGF. Macrophages thus play an important role in cancer progression 
and, consistently, macrophage-deficient mice susceptible to mammary cancer have shown 
delayed tumor progression and metastasis (Lin et al. 2001). 
 
 
2.2 Extracellular matrix molecules 
The extracellular matrix (ECM) is a dynamic structure found around cells in animal tissues, 
in the intercellular space, and is composed of specialized proteins, proteoglycans, and 
glycosaminoglycans secreted by the surrounding cells, mainly fibroblasts. To mention some, 
the specialized proteins include collagens, elastin, laminins, fibronectins, and tenascins, the 
proteoglycans include versican, brevican, perlecan, decorin, and biglycan, and the 
glycosaminoglycans include heparin and hyaluronan. The exact composition of the ECM 
depends on the tissue type and it is subject to constant remodeling. In addition to the 
interstitial matrix between various cells, a specialized form of the ECM, the basement 
membrane (BM, also known as basal lamina), is found as thin sheets underlying epithelial 
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and endothelial cells, and surrounding nerve, muscle, and fat cells, thereby separating them 
from stromal components. The BM also prevents the migration of normal epidermal 
melanocytes into the dermis (Satyamoorthy and Herlyn 2002). The main components of the 
BM are collagen-IV (COL-IV), entactin, laminins (LNs), and heparan sulfate proteoglycans 
like perlecan (Finger and Giaccia 2010). 
 
The most obvious function of the ECM is to provide support and anchorage for the resident 
cells (mainly through the integrin adhesion receptors, see the section 3.1.2), but the 
interactions of ECM molecules are also important in regulation of many cellular processes, 
including cell survival, proliferation, differentiation, cell migration, and cancer cell invasion. 
As the ECM proteins are often large, multi-domain molecules, they are able to interact with 
several other molecules through different domains (nicely reviewed in Hynes 2009). Indeed, 
several families of ECM proteins have domains in common, favoring their mutual 
interactions. In addition, ECM sequesters water and growth factors/angiogenic factors that 
are important for tumor growth. Many of these growth factors, like FGFs and VEGFs, are 
known to bind to the glycosaminoglycan parts of ECM proteoglycans, but increasing 
evidence shows that growth factors can also directly bind to ECM proteins, such as HGF 
binding to fibronectin (FN) and vitronectin (VN), and VEGF binding to FN and tenascin-C 
(TN-C) (Hynes 2009). Further, ECM does not only function as a reservoir for soluble growth 
factors (released by degradation of ECM), but it plays an important role in the presentation of 
growth factor signals. One of the best examples of this role is the regulation of TGF-β 
signaling (reviewed in Hynes 2009). First, the TGF-β precursor is cleaved to the mature TGF-
β molecule (still inactive) and its propeptide (latency-associated peptide, LAP), which still 
remain non-covalently associated and then further bind to latent TGF-β-binding proteins 
(LTBPs) to form large latent complexes. These complexes are bound to the ECM via 
interactions of LTBPs and ECM proteins (including fibrillins and FNs). This LTBP-mediated 
binding of latent TGF-β molecules to the ECM is necessary for their subsequent effective 
activation, which can be triggered by degradation of the ECM proteins, LTBPs, or LAPs, or 
directly by conformational change in LAP, leading to exposed TGF-β able to bind to and 
activate its receptors. Thus, the activated TGF-β growth factor triggers its downstream 
signaling while still remaining bound to the ECM proteins. 
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2.2.1 Collagens 
The main characteristic of the ECM is a collagen (COL) scaffold into which the cells are 
anchored, indirectly via adhesive glycoproteins and proteoglycans or directly via their surface 
collagen receptors (see below). COL is best known as the tensile element of tissues such as 
tendon, cartilage, bone, and skin (elongated COL fibrils, the most abundant structural 
elements in adult tissues) and the main component of BM (COL-IV meshwork) (Kadler et al. 
2007). Collagens (reviewed in Kadler et al. 2007; Heino 2007; Gordon and Hahn 2010), 28 
named to date, represent a large family of triple helical proteins composed of three α chains 
held together by interchain hydrogen bonds. Collagen α chains, in turn, typically contain 
triple helical domains (COL domains), composed of repeated glycine-X-Y motifs (where X 
and Y mean any amino acids, often, however, occupied by proline and 4-hydroxyproline), 
flanked by non-collagenous domains (NC domains). Fibril-forming collagens (the most 
important being COL-I and -III) are synthesized as procollagen molecules containing N- and 
C-terminal propeptides, which are then cleaved by proteinases before fibrillogenesis (Kadler 
et al. 2007).  Collagen fibrils are then further stabilized by non-reducible covalent crosslinks. 
Collagens are mostly synthesized by fibroblasts, myofibroblasts, osteoblasts, and 
chondrocytes (Bosman and Stamenkovic 2003). 
 
In addition to the collagen fibrils, collagens form various other supramolecular aggregates, 
including chicken wire-like networks formed by the BM collagen COL-IV, hexagonal 
networks formed by collagens like COL-X, beaded filaments formed by COL-VI, and 
anchoring fibrils formed by COL-VII (Heino 2007; Gordon and Hahn 2010). Further, fibril-
associated collagens with interrupted triple helices (FACITs, COL-IX as an example) can be 
found at the surfaces of collagen fibrils mediating their interactions with other matrix 
proteins. Transmembrane collagens (COL-XIII, -XVII, -XXIII, and -XXV), in turn, are 
inserted into the plasma membrane and multiplexins (COL-XV and -XVIII) participate in the 
stabilization of BM structures (Heino 2007; Gordon and Hahn 2010). The most abundant 
collagens, COL-I and -II are able to spontaneously form fibrils in vitro, but in vivo they need 
non-collagenous molecules like FN and FN- and COL-binding integrin receptors as 
organizers (COL-I), and COL-V (COL-I) or COL-XI (COL-II) to initiate the process (Kadler 
et al. 2008). In addition to these interaction partners, numerous other molecules have been 
shown to influence collagen fibrillogenesis, including tenascin-X (Kadler et al. 2008). 
Indeed, COL-I is known to have nearly 50 binding partners (Di Lullo et al. 2002). 
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The main cellular collagen receptors are integrins (integrins α1β1, α2β1, α10β1, and α11β1 
being the most important), but also receptor tyrosine kinases (discoidin domain receptors 1 
and 2) and immunoglobulin-like receptor family members (glycoprotein VI and leukocyte-
associated immunoglobulin-like receptor-1) are known to bind collagens, as well as 
proteoglycans (CD44, syndecans, and glypicans) (Heino 2007). Collagen fibrils play a central 
role in various physiological processes like embryogenesis, tissue repair, fibrosis, and tumor 
invasion (Kadler et al. 2008). 
 
 
2.2.2 Elastin 
Another key structural component of the ECM is elastin (reviewed in Mithieux and Weiss 
2005; Muiznieks et al. 2010). Elastin is a self-assembling protein providing elasticity to 
vertebrate tissues dependent on repeated distension and relaxation, such as large arteries, 
lung, skin, bladder, ligaments, tendons, and elastic cartilage.  Elastin self-assembly involves 
self-association of the soluble tropoelastin precursor molecules through hydrophobic domains 
(a process known as coacervation) followed by massive cross-linking accomplished by lysyl 
oxidases. This cross-linking is indeed essential for the function of elastin. Tropoelastin 
monomers are typically secreted by fibroblasts, vascular smooth muscle cells, endothelial 
cells, and chondrocytes (Mithieux and Weiss 2005; Rodgers and Weiss 2005). In the ECM, 
elastin is found as the main component (90%) of elastic fibers, forming the internal core of 
the fibers. This core is interspersed with and surrounded by unbranched microfibrils (the 
main components being fibrillin-1 and -2, and microfibril-associated glycoprotein-1), which, 
in fact, precede the self-assembly of tropoelastin molecules and act as a scaffold for their 
deposition (Mithieux and Weiss 2005; Muiznieks et al. 2010). Other proteins present in the 
elastic fibers include VN, LTBPs (see above), microfibrillar associated proteins, and 
proteoglycans such as versican, biglycan, and decorin (Mithieux and Weiss 2005). The 
elastin receptors studied include elastin binding protein, a G protein-coupled receptor, and 
integrin αVβ3 (Rodgers and Weiss 2005). Interestingly, elastin has a half-life of about 70 
years, and thus very little turnover is seen during the adult life (Mithieux and Weiss 2005). In 
addition to barely providing elasticity to the tissues, elastin, tropoelastin, and elastin 
degradation products are nowadays known to influence cellular responses, including 
chemotaxis, proliferation, and cell adhesion (Rodgers and Weiss 2005). 
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2.2.3 Laminins 
LNs (reviewed in Miner 2008; Durbeej 2010), the major constituents of BM, are cross- , Y-, 
or rod-shaped heterotrimeric proteins forming polymeric networks able to bind other matrix 
proteins (also interacting with each other), thus organizing the formation of a highly cross-
linked structure of BM. LNs, synthesized by numerous cell types, are composed of one α-, 
one β-, and one γ-chain, all sharing a common domain structure consisting of a number of 
globular and rod-like domains. In vertebrates, there exist five α, three β, and three γ-laminin 
chains, and their heterotrimers show tissue-specific distribution. The LN heterotrimers are 
assembled inside the cell, but further proteolytic processing occurs outside the cell to produce 
the mature protein and, finally, the LNs form the BM networks. In addition to other ECM 
molecules, LNs interact with cell surface receptors, linking them to intracellular signaling 
pathways. The major LN receptors are integrins (including α6β1, α6β4, and αVβ3) and non-
integrin receptors (including dystroglycan, syndecans, and Lutheran blood group 
glycoprotein).  LNs are essential for early embryonic development and organogenesis 
(Durbeej 2010), but they seem to play a role in malignancy as well (Patarroyo et al. 2002). 
Notably, LN (LN-111) is also one of the main components of Matrigel, a basement 
membrane-like matrix extracted from murine sarcoma tumor, which has been extensively 
utilized in cancer research (Benton et al. 2011). 
 
 
2.2.4 Fibronectin 
FN molecules (reviewed in Pankov and Yamada 2002; Kaspar et al. 2006) are ubiquitous 
high-molecular-weight ECM glycoproteins forming covalently-linked dimers, which 
assemble into a fibrillar matrix (Singh et al. 2010). This matrix is relevant for several cellular 
processes, including cell adhesion, migration, growth, and differentiation, and, consistently, 
FN is essential for early embryonic development. Further, FN plays an important role in 
wound healing, where FN is included in the initial clot, together with fibrin and platelets, and 
further in the FN-rich granulation tissue, the young connective tissue later displaced by the 
collagenous matrix of the scar (Dvorak 1986). FN is also a component of tumor stroma 
(Dvorak 1986). 
 
FN monomers consist of three types of repeating units, FN repeats type I, II, and III, which 
account for approximately 90% of the FN sequence. These units fold into a series of protein 
 25 
 
domains, often displaying functionally distinctive properties (Kaspar et al. 2006). Indeed, FN 
molecules are known to possess a collagen-binding domain and heparin-binding domains, as 
well as fibrin- and integrin-binding sites (including the RGD sequence), through which they 
interact with other ECM macromolecules and cell surface integrins (the most important being 
integrins α5β1 and αVβ3). Indeed, even the FN polymerization, the FN fibrillogenesis, 
requires direct interactions with the integrin receptor α5β1 (Kadler et al. 2008; Singh et al. 
2010). Further, FN molecules bind to each other, which is essential for fibril formation 
(Singh et al. 2010). As mentioned above, FN also functions as an organizer in collagen 
fibrillogenesis, and the assemblies of FN and COL fibrils seem to be dependent on each other 
(Kadler et al. 2008; Singh et al. 2010). Further, FN matrix is required for the assembly of 
microfibrils, which, in turn, have an important role in elastic fiber assembly, and for the 
incorporation of growing number of other ECM proteins (including LTBPs and TN-C) into 
the matrix (Singh et al. 2010). In addition to the insoluble ECM FN, liver hepatocytes secrete 
soluble FN found in plasma and other body fluids (Pankov and Yamada 2002). The single FN 
gene gives rise to multiple variant molecules by alternative splicing and these variants have 
different cell-adhesive, ligand-binding, and solubility properties (Pankov and Yamada 2002). 
As this spicing is cell type-specific, cells can utilize FN variants in a developmental and 
tissue-specific manner. 
 
 
2.2.5 Tenascins 
Tenascin (TN) family (reviewed in Jones and Jones 2000; Bosman and Stamenkovic 2003; 
Midwood and Orend 2009) contains the high-molecular-weight glycoproteins tenascin-C, -R, 
-W, -X, and -Y. Of these, TN-C, which was discovered first and is the most extensively 
studied, forms hexamers (hence also called hexabrachion) and functions to modulate cell 
migration, proliferation and cellular signaling. The other members of TN family, in turn, 
most often form trimers. In addition to the oligomerization domain, TNs have varying 
numbers of EGF-like repeats, various FN type III domains, and a fibrinogen-like globular 
domain, making them able to interact with numerous ECM proteins and proteoglycans, 
including FN (Chiquet-Ehrismann et al. 1988; Chung et al. 1995) and COL-I (Di Lullo et al. 
2002), and multiple cell surface receptors, such as integrins α2β1, α7β1, α9β1, and αvβ3, and  
EGF receptor (Midwood and Orend 2009). In contrast to FN, being an adhesive ECM 
protein, TN-C is mainly anti-adhesive and can interfere with cell attachment to FN and LN 
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(Chiquet-Ehrismann et al. 1988; Herlyn et al. 1991). Like FN, also TNs have several 
alternatively spliced isoforms, having different adhesive properties and showing tissue and 
cell type-specificity. TN-C is highly expressed during embryogenesis, but it is largely absent 
in normal adult tissues. Its expression is, however, specifically induced at sites of 
inflammation, wound healing, and neovascularization, and persistently induced in fibrotic 
diseases and in solid tumors (Midwood and Orend 2009). TN-C is known to be produced by 
stromal fibroblasts, both in healing wounds and in tumors, and by osteoblasts, perichondrial 
cells, and muscle cells (Chiquet-Ehrismann and Tucker 2004), but some tumor cells also 
produce TN-C, including melanoma cells (Herlyn et al. 1991). Interestingly, TN-C has been 
found to stimulate MMP expression, including MMP-1 (Fukunaga-Kalabis et al. 2008). 
 
 
2.2.6 Transforming growth factor beta-induced 
Of the minor ECM proteins, transforming growth factor beta-induced (TGFBI, originally 
known as βig-h3, also keratoepithelin) is an interesting protein expressed ubiquitously in 
various tissues, except the brain (Skonier et al. 1994; Ivanov et al. 2008). It is a TGF-β-
inducible, 68 kDa secreted protein containing an N-terminal secretory signal peptide, a 
cysteine-rich domain (EMI), four consecutive fasciclin 1 (FAS) repeats, and a C-terminal 
Arg-Gly-Asp (RGD) motif (Skonier et al. 1992). TGFBI has been found to interact with 
several other ECM components, including COL-I, -II, -IV and -VI, FN, LN, periostin, and 
proteoglycans like biglycan and decorin (Hashimoto et al. 1997; Billings et al. 2002; Kim et 
al. 2002; Reinboth et al. 2006; Kim et al. 2009). Further, TGFBI has been shown to directly 
(independent of other macromolecules) bind to collagen fibers of the triple helical 
conformation (not binding to denatured COL-I, gelatin), whereas FN binds both collagens 
and gelatin (Hashimoto et al. 1997). In addition, TGFBI has been shown to interact with 
various cell surface integrins (Thapa et al. 2007), and because of this feature and the RGD 
motif, has been thought to function as a linker between ECM and the cell surface integrins. 
TGFBI function is related to cell adhesion, but opposite results have been achieved in 
adhesion experiments: TGFBI has been shown to promote the adhesion of some cell types, 
including human dermal, lung, and bladder fibroblasts (LeBaron et al. 1995; Ohno et al. 
1999; Billings et al. 2002), corneal epithelial cells (Kim et al. 2000), keratinocytes (Bae et al. 
2002), and endothelial cells (Nam et al. 2003), but to inhibit the adhesion of human lung 
adenocarcinoma cells, HeLa cells, lung fibroblasts (Skonier et al. 1994),  and scleral 
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fibroblasts (Shelton et al. 2008; Shelton and Summers-Rada 2009). Thus, TGFBI’s role in 
cell adhesion may depend on the cell type and the molecules of the microenvironment. In line 
with its multiple interaction partners, TGFBI has been shown to participate in multiple 
physiological as well as pathological processes, including morphogenesis, 
adhesion/migration, corneal dystrophy, wound healing, inflammation, and tumorigenesis 
(reviewed in Thapa et al. 2007). 
 
 
 
3. LOCAL INVASION 
Disaggregation of tumor cells and their movement into the surrounding tissues are the first 
steps in metastatic spread. For this, modification of cell-cell and cell-ECM interactions is 
essential, as well as increased proteolysis to remove physical obstruction created by the 
ECM. 
 
 
3.1 Cell adhesion and adhesion receptors 
To maintain normal tissue architecture the cells need to maintain proper contacts with their 
neighboring cells and the ECM. Invading cancer cells, in turn, need to break the existing 
contacts and to make new contacts that are beneficial to them. In addition to cancer cell 
invasion, a similar ability to change adhesion partners is needed during normal embryonic 
development and the healing of tissue injuries. 
 
 
3.1.1 Cell-cell interactions 
The family of classical cadherins, of which the type I cadherins E-cadherin (epithelial), N-
cadherin (neural), and P-cadherin (first identified in placenta) are the best characterized, 
consists of transmembrane adhesion molecules mediating calcium-dependent cell-cell 
interactions (reviewed in Behrens 1999; Angst et al. 2001; Rickelt et al. 2008). With their 
cytoplasmic regions, classical cadherins interact with the actin cytoskeleton via the 
cytoplasmic proteins α-, β-, and γ-catenin, and this interaction, directly connecting the 
cytoskeletons of the adjacent cells, is crucial for efficient cell-cell adhesion. During 
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melanoma development, melanoma cells switch their cadherin expression profile, usually 
during the transition from RGP to VGP (reviewed in  Satyamoorthy and Herlyn 2002; Rickelt 
et al. 2008; Villanueva and Herlyn 2009). In the normal skin environment, epidermal 
keratinocytes and melanocytes both express E-cadherin (and to lesser extent also P-cadherin), 
that mediates their homophilic interaction controlling melanocyte proliferation. The dermal 
fibroblasts and vascular endothelial cells, in turn, express N-cadherin at their surfaces. During 
melanoma development, melanoma cells down-regulate E-cadherin and P-cadherin 
expression, and up-regulate N-cadherin expression, thereby reducing their interaction with 
the division-controlling keratinocytes, and promoting interactions with fibroblasts and 
endothelial cells. This may facilitate the migration/invasion of melanoma cells into the 
dermis and intravasation into the vasculature. A similar cadherin profile switch occurs in the 
progression of epithelial cancers, in EMT. In this process, the non-motile, polarized epithelial 
cells are transformed into motile, non-polarized mesenchymal cells able to disseminate 
(Finger and Giaccia 2010). 
 
 
3.1.2 Cell-matrix interactions 
Integrins are the main cellular receptors used for cell-ECM adhesive interactions (reviewed in 
Giancotti and Ruoslahti 1999). Additionally, some leukocytic integrins are involved in cell-
cell interactions. Integrins are obligate heterodimers, consisting of transmembrane α and β 
subunits, which are non-covalently linked to each other.  In mammals, there exist 18 α and 8 
β subunits, forming at least 24 integrin dimers. The subunit composition of integrin dimers 
confers them specificity to different ligands, like COL, FN, LN, TN, and VN. Most integrins 
have several ligand molecules and multiple integrins can recognize the same ligand molecule. 
While integrins bind their ECM ligands through their large extracellular domains, their small 
cytoplasmic tails are linked to the actin cytoskeleton via a variety of linker proteins, such as 
talin, α-actinin, vinculin, and paxillin. Following ligand binding, integrins trigger 
reorganization of the cytoskeleton. In addition to anchoring of the cells into the surrounding 
ECM, integrins mediate bidirectional signals between the cells and ECM. First, integrins can 
be activated by cytoplasmic molecules, like talin, leading to “inside-out” signaling. When 
binding to their ECM ligands, integrins undergo conformational changes and activate 
multiple cytoplasmic signaling pathways (“outside-in” signaling). Integrins become clustered 
upon ligand binding. When integrins bind their ECM ligands and associate with the 
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cytoskeletal and signaling complex, they form protein aggregates on both sides of the 
membrane. This property of integrins to serve as integrators of the ECM and cytoskeleton has 
given them their name. In cell cytoplasm, integrins, not having any enzymatic activity of their 
own, activate various protein tyrosine kinases, including focal adhesion kinase (FAK) and 
Src-family kinases, which, in turn, activate various signaling pathways. Further, integrins are 
also necessary for optimal activation of growth factor receptors. Numerous studies have 
reported altered integrin expression in different cancers and integrins have been shown to 
clearly contribute to cancer progression (reviewed in Desgrosellier and Cheresh 2010; 
Rathinam and Alahari 2010). 
 
In addition to the large family of integrins, also non-integrin receptors to ECM molecules 
exist on the cell surface. These include for instance the FN-binding syndecans, the LN-
binding 67 kDa LN receptor and α-dystroglycan, the COL-binding discoidin domain 
receptors, glycoprotein VI, and leukocyte-associated immunoglobulin-like receptor-1, and the 
hyaluronan binding hyaladherins (like RHAMM and CD44) (Heino and Käpylä 2009). 
Nevertheless, these non-integrin receptors often show more limited tissue distribution than 
the integrins and function in collaboration with the integrin receptors. 
 
 
3.2 Cell migration 
In addition to cancer cell invasion and metastasis, cell motility is essential for many 
physiological processes, including embryonic development, wound healing and 
inflammation. Cell migration occurs due to cycles of five independent steps (Wolf and Friedl 
2006). First, membrane protrusion formation (lamellipodia, filopodia, or pseudopodia, or 
invadopodia in invading cancer cells in 3D-matrix) and polarization are initiated by actin 
polymerization (in an adhesion-independent manner), and after that, the cell protrusions 
adhere to the ECM molecules (integrins being also the major migration-mediating receptors) 
forming focal adhesion sites. At this stage, also the cell surface proteases may become 
recruited to the attachment sites, to cleave the matrix barriers. Next, actomyosin contraction 
of the cell body creates bipolar tension in the cell body, and, finally, this tension leads to the 
cell body translocation and tail retraction. 
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3.2.1 Actin polymerization 
The driving force in eukaryotic cell motility is polymerization of actin monomers (G-actin) 
into polarized filaments (F-actin) (Pollard and Borisy 2003). New monomers are constantly 
added at the “barbed” or “plus” ends of the filaments and, simultaneously, the “pointed” or 
“minus” ends are depolymerized. The predominant site of actin polymerization in motile cells 
is proximal to the plasma membrane, and the actin filaments are oriented in the direction of 
the movement, barbed ends directed towards the plasma membrane (Olson and Sahai 2009). 
Actin polymerization in motile cells can be enhanced in many ways: formin homology (FH) 
proteins increase the rate of polymerization at the barbed ends (generating linear F-actin 
arrays found in filopodia), the Arp2/3 complex binds to the actin filament and nucleates a 
branching point, thereby increasing the number of barbed ends (generating sheets of F-actin 
found in lamellipodia), and cofilin creates new barbed ends by cutting existing actin filaments 
(reviewed in Olson and Sahai 2009). In addition to polymerization enhancing molecules, 
capping proteins are used to sterically hinder monomer addition. Further, the availability of 
actin monomers is regulated by maintaining them complexed with profilin or thymosin. Of 
these actin sequestering molecules, thymosins β4 and β10 (Tβ4 and Tβ10) play a major role 
(reviewed in Mannherz and Hannappel 2009). Tβ4 and Tβ10 bind G-actin at 1:1 
stoichiometric ratio and maintain a dynamic equilibrium between G- and F-actin.  From this 
pool of G-actin, the actin monomers can easily be used for actin polymerization when 
needed, but inappropriate polymerization is prevented. 
 
As actin cytoskeleton and actin polymerization are enormously important for the cell, the 
activity of the complex polymerization machinery must be tightly regulated (reviewed in 
Olson and Sahai 2009). To mention some regulatory molecules, the Arp2/3 complex is 
regulated by the WAVE and WASP family proteins, binding both the Arp2/3 complex and 
actin monomers, and thereby increasing the rate of actin polymerization. The WAVE and 
WASP family proteins, as well as FH proteins, are, in turn, also tightly regulated themselves 
through a conformational switch. Their inactive “closed” conformation can only become 
active “open” conformation after interactions with GTP-binding proteins like Cdc42 (WASP 
and FH), RhoA, RhoB, and Rif (FH), and various adaptor molecules. In addition, many 
regulators of actin polymerization are themselves regulated by phosphorylation. The goal of 
these complex regulatory mechanisms is to ensure that inappropriate actin polymerization 
does not occur, and, on the other hand, to enable increased actin polymerization in response 
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to appropriate stimuli. Accordingly, many of these multiple regulatory pathways have 
become deregulated in invasive cancer cells (coordinated up-regulation) (Olson and Sahai 
2009). 
 
 
3.2.2 Acto-myosin contraction 
Cell movement needs, in addition to actin polymerization, force generation accomplished by 
the myosin family of motor proteins (reviewed in Vale and Milligan 2000; Olson and Sahai 
2009).  For that, the polymerized actin filaments assemble with myosin II filaments, 
composed of heavy and regulatory light chains, and the associated myosin molecules then use 
energy from ATP hydrolysis to move towards the barbed end of the actin filament. When 
multimeric myosin is associated with multiple actin filaments, this movement causes the actin 
filaments to move relative each other, generating the contractile force driving morphological 
reorganization. Not surprisingly, this step of cell movement is tightly regulated as well. The 
key mechanism for regulation of actin-myosin contractibility is phosphorylation of the 
myosin II light chain, accomplished by numerous kinases, promoting the formation of myosin 
filaments and facilitating the association with F-actin. 
 
The processes of actin polymerization and contraction are both essential steps of cell motility 
and for effective movement they must be coordinated. Polymerization needs to occur prior to 
contraction and more proximal to the plasma membrane (Olson and Sahai 2009). As actin 
polymers are oriented barbed ends directed towards the plasma membrane, the more recently 
polymerized actin exists adjacent to plasma membrane and the older F-actin is further away. 
Indeed, newly polymerized actin is not associated with the contractile machinery. Anyhow, it 
is not clear yet how this spatial and temporal separation is achieved. 
 
 
3.3 Proteolysis of extracellular matrix 
Invading cancer cells use proteolytic enzymes to break down the surrounding ECM, thereby 
clearing a path for the migrating tumor cells and liberating/activating beneficial growth 
factors and angiogenic factors anchored in the ECM. As mentioned above, also activated 
fibroblasts and macrophages residing in the tumor microenvironment play a significant role 
in ECM degradation by producing ECM modifying proteases. In addition to being the major 
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migration-mediating receptors (see above), the integrins also assist in targeted ECM 
remodeling by influencing protease expression and localizing them near their substrates 
(Ivaska and Heino 2000). 
 
 
3.3.1 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases involved 
in various physiological processes including tissue remodeling and organ development, as 
well as regulation of inflammatory processes. Most importantly, MMPs have been thought to 
be the main proteases behind cancer cell invasiveness (reviewed in Ala-aho and Kähäri 2005; 
Hofmann et al. 2005; Kessenbrock et al. 2010; Bourboulia and Stetler-Stevenson 2010). The 
family of human MMPs, comprising 23 members (both secreted and membrane bound), is 
divided into five main groups according to their structure and substrate specificity: 
collagenases, gelatinases, membrane type MMPs, stromelysins, and matrilysins (Bourboulia 
and Stetler-Stevenson 2010). To mention some, MMP-2 and MMP-9 degrade COL-IV, the 
major component of BM, and MMP-1 degrades type I, II, and III collagens (Finger and 
Giaccia 2010). Collectively MMPs are able to degrade all the components of ECM. In normal 
intact tissues, MMPs are expressed at low levels, but when tissue remodeling is needed, their 
expression is induced by signals such as growth factors, cytokines, and physical stress (Ala-
aho and Kähäri 2005). Most MMPs are secreted as inactive proproteins, which are active only 
after proteolytic cleavage accomplished by other MMPs or serine proteases like plasmin (see 
below), or intracellularly by furin (Kessenbrock et al. 2010). Further, MMPs are additionally 
kept in check by tissue inhibitors of metalloproteinases (TIMPs) and inhibitors secreted by 
the liver (such as α2-macroglobulin). In invasive tumors, the levels of active MMPs (as well 
as TIMPs) are usually increased, originating from secretion by both tumor cells and stromal 
cells (the major source) such as tumor-associated inflammatory cells (especially 
macrophages), activated fibroblasts, and endothelial cells (Kessenbrock et al. 2010). 
Melanoma cells have been reported to express various MMPs, including MMP-1, -2, -9, -13, 
and MT1-MMP (Hofmann et al. 2005 and the references therein). 
 
In addition to making space for the invading cancer cells by ECM degradation, MMPs also 
promote tumor progression in multiple other ways. MMPs for instance influence the 
bioavailability or functionality of various important factors, such as ECM sequestered growth 
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factors (an important representative being TGF-β) and angiogenic/lymphangiogenic factors 
(like VEGF), as well as chemokines and proinflammatory cytokines recruiting inflammatory 
cells (reviewed in Kessenbrock et al. 2010). MMPs also degrade cell surface E-cadherin 
molecules, thereby disrupting cell-cell interactions, and interfere with the induction of 
apoptosis. Importantly, MMPs are now known to interact with cell surface receptors, such as 
integrins, (which also influence MMP expression), providing a way to localize them near 
their substrate molecules (a process called integrin-guided proteolysis; Ivaska and Heino 
2000). Interestingly, MMP-3 has also been related to tumor initiation (Sternlicht et al. 1999). 
In contrast to their invasion-promoting effects, MMP catalyzed degradation of collagens and 
plasminogen has also been shown to generate anti-angiogenic fragments, and the catalytic 
function of some MMPs, such as MMP-8 in melanoma, have been shown to suppress the 
metastatic behavior (Gutiérrez-Fernández et al. 2008; Palavalli et al. 2009). Further, in 
addition to the traditional proteolytic-dependent roles, MMPs have more recently been 
reported also to have non-catalytic functions, where the hemopexin domain plays an 
important role. These functions include enhanced cell migration (MMP-2, -9, and -14), 
antimicrobial function (macrophage elastase MMP-12), and inhibition of the complement 
system (MMP-14) (Kessenbrock et al. 2010). 
 
Besides MMPs, also closely related families of ADAMs (a disintegrin and 
metalloproteinases) and ADAMTSs (ADAMs with thrombospondin type 1 motifs) that share 
the metalloproteinase domain with MMPs, have recently been related to cancer development 
and progression (reviewed in Rocks et al. 2008; Klein and Bischoff 2011). Indeed, 
dysregulated expression of both types of molecules has been reported in various cancers. 
ADAMs (nicely reviewed in Toriseva and Kähäri 2009; Klein and Bischoff 2011) are 
transmembrane proteins possessing both adhesive and proteinase activities (12 of the 22 
known human ADAMs display proteolytic activity; Klein and Bischoff 2011) and mainly 
functioning as sheddases, cleaving and releasing membrane bound proteins including 
cytokines and growth factors, and their receptors, as well as adhesion proteins and proteases. 
By liberating these biologically active proteins, ADAMs are known to regulate cell 
proliferation. ADAMTSs, in turn, are secreted proteases that mainly cleave ECM proteins. 
The proteolytic activities of ADAMs are known to be inhibited by certain integrins, α2-
macroglobulin and, to some extent, also by TIMPs, and those of the ADAMTSs by TIMPs. 
Similarly to some MMPs showing a tumor progression-inhibiting function (such as MMP-8), 
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also some ADAMs and ADAMTSs have been recently shown to possess anti-angiogenic 
activities (Rocks et al. 2008). 
 
 
3.3.2 Serine proteases 
The serine protease family contains e.g. the digestive enzymes chymotrypsin, trypsin, and 
elastase, as well as mast cell tryptase and chymotryptase, and neutrophil cathepsin G. It also 
includes the urokinase plasminogen activator system, which plays an important role in tumor 
cell invasion and metastasis (reviewed in Dass et al. 2008). This system in turn consists of 
urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA), the 
uPA receptor (uPAR), and plasminogen activator inhibitors (PAIs). Several malignant tumors 
have been shown to overexpress uPA and uPAR, including breast and ovarian cancers. uPA 
catalyzes the cleavage of plasminogen into plasmin, a broad-spectrum serine protease directly 
degrading ECM components and activating MMPs. uPA itself is secreted as an inactive 
zymogen, which, in turn, is cleaved to its active form by plasmin (a feed-back-type 
activation). Before its activation uPA binds to its receptor uPAR, which is attached to the 
plasma membrane via a glycosyl phosphatidyl inositol anchor. tPA serves the same roles as 
uPA, but it is mainly involved in intravascular thrombolysis, whereas uPA is involved in 
pericellular proteolysis during migration, wound healing, and tissue remodeling. The 
plasminogen activator inhibitors, PAI-1 and PAI-2, function to keep the activities of uPA and 
tPA in control, but, interestingly, PAI-1 has been reported to also facilitate tumor growth and 
angiogenesis. 
 
 
3.3.3 Cysteine proteases 
Cysteine cathepsins, belonging to the papain subfamily of cysteine proteases, are lysosomal 
proteases related to tumor dissemination, as well as angiogenesis (reviewed in Mohamed and 
Sloane 2006; Gocheva and Joyce 2007; Vasiljeva and Turk 2008). The family of human 
cysteine cathepsins comprises 11 members, cathepsins B, C, F, H, L, K, O, S, V, W, and X/Z, 
of which especially cathepsins B and L often show up-regulation in human malignancies, 
including melanoma (Gocheva and Joyce 2007; Vasiljeva and Turk 2008). Cathepsins are 
synthesized as inactive precursors, zymogens, which are then activated by proteolytic 
removal of the N- terminal propeptide (Vasiljeva and Turk 2008). In normal cells, the main 
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function of cathepsins is terminal protein degradation in the lysosomes, but they also 
participate in MHC class II-associated antigen processing and presentation, and bone 
remodeling (Mohamed and Sloane 2006; Vasiljeva and Turk 2008). In addition, cysteine 
cathepsins participate in pathological conditions, such as rheumatoid arthritis and 
atherosclerosis (Vasiljeva and Turk 2008). During malignant progression, cysteine cathepsins 
promote tumor cell invasion through several mechanisms: by directly cleaving ECM 
components (including LN, FN, TN-C, and COL-IV), by activating other proteases (such as 
pro-MMPs and pro-uPA) leading to activation of proteolytic cascades degrading ECM 
molecules, and by cleaving cell surface E-cadherin molecules resulting in disrupted cell-cell 
interactions (Gocheva and Joyce 2007). In addition to promoting tumor cell invasion, 
cysteine cathepsins have, interestingly, been shown to mediate cell apoptosis (Vasiljeva and 
Turk 2008). A key feature separating these two opposing functions appears, however, to be 
differential distribution: secreted or plasma membrane-associated cathepsins participate in 
tumor cell invasion, whereas cytosol translocated cathepsins trigger apoptosis (Vasiljeva and 
Turk 2008). In addition to tumor cells themselves, also other cell types of the tumor 
microenvironment have been shown to express cathepsins, including tumor-associated 
fibroblasts and macrophages (Mohamed and Sloane 2006). Interestingly, the AdoMetDC-
transformed mouse fibroblasts used in this study (Amdc-s cells) have been found to show 
highly increased secretion of pro-cathepsin L as compared to normal fibroblasts (Ravanko et 
al. 2004). Indeed, cathepsin L was found to account for the major protease activity in these 
highly invasive cells, and cathepsin L inhibitors were able to totally inhibit the invasion of 
these cells in Matrigel (Ravanko et al. 2004). 
 
Altogether, in addition to heterotypic signaling and cell adhesion, proteolytic activity is one 
of the most important aspects of cancer progression. As proteases are collectively able to 
cleave all the ECM molecules, they make it possible for the cancer cells to invade the 
surrounding tissues and to intravasate or extravasate the blood and lymphatic vessels. The 
most important effector proteases behind these events may be MMPs, but serine and cysteine 
proteases also play an important role, especially in the activation of proteolytic cascades. In 
addition to making space for the invading cancer cells, the proteolytic networks also 
influence the effects of various growth factors and cytokines, thereby influencing heterotypic 
signaling, and disrupt cell adhesions. An opposite role, the suppression of cancer progression, 
has, however, been reported for some of the MMPs, and cysteine cathepsins have been found 
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to mediate cell apoptosis. These more recent findings make following the story of proteases 
in cancer very interesting. 
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AIMS OF THE STUDY 
 
The aim of this study was to search for molecules that are relevant for the high invasiveness 
of fibrosarcoma and melanoma cells by comparing the gene expression patterns of 
representative malignant cells to those of corresponding normal cells. Further, an attempt was 
made to functionally characterize the most interesting molecules and to analyze their 
potential for cancer biomarkers or therapeutic targets. 
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MATERIALS AND METHODS 
 
1. CELL LINES AND TISSUE SPECIMENS (I-IV) 
The cell lines used in this study are detailed in Tables 1 and 2. Mouse cell lines Amdc-s, 
Amdc-as, and E4 are transformed fibroblasts (fibrosarcoma cells), and 4N and N1 are 
corresponding normal cells. Amdc-s-pLRT-Tβ4-as and Amdc-as-pLRT-Tβ4-as are 
transformed fibroblasts with inducible expression of thymosin β4 antisense-RNA, whereas 
Amdc-pLRT-TAM67 cells show inducible expression of TAM67, a dominant-negative 
mutant of c-Jun. HT-1080 is a human fibrosarcoma cell line originating from a clinical 
fibrosarcoma tumor. 
 
The human cell lines WM793 and WM239 are invasive melanoma cells isolated from 
primary melanoma and melanoma metastasis, respectively, whereas 42V and Mela3 are 
normal melanocytes. PMEL29 cells are invasive melanoma cells isolated from a primary 
melanoma tumor, primary fibroblasts are isolated from normal adult skin, and TGFBI-KD 
cells are melanoma cells expressing TGFBI shRNA. 
 
Table 1. Mouse cell lines. 
Name   Parental cell line Vector  Vector insert  Publication 
4N   NIH3T3  pLTRpoly -   I-II 
Amdc-s   NIH3T3  pLTRpoly AdoMetDC sense  I-II 
Amdc-as*  NIH3T3  pLTRpoly AdoMetDC antisense I 
N1   NIH3T3  pSV2neo  -   I 
E4   NIH3T3  pGEJ6.6  c-Ha-rasVal12  I 
Amdc-s-pLRT-Tβ4-as§ Amdc-s  pLRT  Tβ4 antisense-RNA I 
Amdc-as-pLRT-Tβ4-as§ Amdc-as  pLRT  Tβ4 antisense-RNA I 
Amdc-pLRT-TAM67§ Amdc-s  pLRT  TAM67   I-II 
*To prevent the counter selection of Amdc-as cells expressing AdoMetDC antisense-mRNA at levels sufficient to block the 
synthesis of essential polyamines, a low concentration (1 μM) of spermidine was added to the growth medium.  
§For induction of Tβ4 antisense-RNA or TAM67 expression, 1 μg/ml doxycycline was added the day after plating.  
 
Table 2. Human cells. 
Name  Cell type     Publication 
HT-1080  Fibrosarcoma cell line   II 
42V  Primary melanocytes   I, III-IV 
Mela3  Primary melanocytes   IV 
WM793  Melanoma cell line (VGP)*   I, III-IV 
WM239  Melanoma cell line (metastatic)  I, III-IV 
PMEL29  Primary melanoma cells   III 
Fibroblast Primary culture of adult skin fibroblasts IV 
TGFBI-KD WM239 cells expressing TGFBI shRNAs IV 
*VGP = vertical growth phase 
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Tissue specimens of benign nevi (n = 32; from healthy volunteers), primary melanomas (n = 
101), clinically detected melanoma metastases (n = 19), and soft-tissue sarcomas (n = 24) 
were obtained from surgical excisions at the Helsinki University Central Hospital. The 
protocols for taking the specimens have been approved by the local ethical committee. 
Further, informed consent was given by the patients before operations. The primary 
melanomas were mostly from patients with cutaneous nodular melanomas with a thickness of 
≥1 mm or Clark’s level IV-V. For RNA isolation, the tissue specimens were frozen in liquid 
nitrogen, and for immunohistochemistry (IHC), the paraffin-embedded tissue samples were 
obtained from the Department of Pathology, Helsinki University Central Hospital or other 
hospitals of the district. In addition to human patient specimens, paraffin-embedded tissue 
samples of nude mice bearing tumors induced by Amdc-s cells or TGFBI short hairpin RNA 
(shRNA) expressing WM239 cells (or their control, non-target shRNA expressing cells) were 
used. 
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2. ANTIBODIES (I-IV) 
The antibodies used in this work are presented in Table 3. In function blocking experiments, 
the neutralizing antibody was preincubated for 30 min with the cells and was also included in 
the growth medium/matrix. 
 
Table 3. Antibodies. 
Target  Clone/Code Source  Specificity* Publication Method**                
Actin  JLA20  mouse  br  II  WB 
c-Jun/AP-1 Ab-1  rabbit  h, m, r  II  WB 
c-Jun  L70B11  mouse  h, m, r, mk II  WB 
  ab31419  rabbit  h, m, r, mk II  WB 
  E254  rabbit  h, m, r  II  IHC 
p-c-Jun  9164  rabbit  h, m, r  II  IHC 
COL-I  ab6308  mouse  h, r, b, mk IV  IF 
FN  NCL-FIB  mouse  h  III, IV  IHC 
  IST-4  mouse  h  III  IHC 
  BP8036  rabbit  h  IV  IF 
Itgα6  MA6  rat  m  II  IF, IP 
  GoH3  rat  h, b, m  II  FC, IP, FB 
  H-87  rabbit  m, r, h  II  IHC  
  3750  rabbit  h, m, r, mk II  WB 
  HPA012696 rabbit  h  II  WB 
ItgαV  AV1  mouse  h  IV  IF 
Itgβ1  AB1952  rabbit  h, m, r  II  WB 
  HA2/5  hamster  r, m  II  FB 
  6S6  mouse  h  II  FB 
  P5D2  mouse  h  IV  IF 
Itgβ4  346-11A  rat  m  II  WB 
  M126  mouse  h, m, r  II  WB 
Itgβ7  FIB27  rat  m  II  FB 
  M293  rat  m  II  IF 
PCOL-I  M-58  mouse  h  III  IHC 
P-FAK (Y397) ab4803  rabbit  h, m  IV  IF 
Tβ4  1-43  rabbit  h  I, IV  IF 
  1-14  rabbit  h  UP§  IHC 
TGFBI  10188-1-AP rabbit  h, m  IV  WB, IHC 
  2719  rabbit  h  IV  IF 
TLN  TD77  mouse  h  IV  IF 
TN-C  BC-24  mouse  h  III  IHC 
  DB7  mouse  h  III  IHC 
α-tubulin  600-401-880 rabbit  br  II  WB 
  DM1A  mouse  br  IV  IF 
β-tubulin  ab21057  goat  h  IV  IF 
Vinculin  VIIF9  mouse  b, h, m, mk, rb IV  IF 
VN  8E6(LJ8)  mouse  h  IV  IF 
*br=broad range, h=human, m=mouse, r=rat, mk=monkey, b=bovine, rb=rabbit 
§UP=unpublished 
**WB=Western blotting, IHC=immunohistochemistry, IF=immunofluorescence staining, IP=immunoprecipitation, FC=flow 
cytometry, FB=function blocking 
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3. RNA ANALYSES (I-IV) 
 
3.1 Microarray analyses (I-IV) 
PolyA RNAs or total RNAs, extracted from cell pellets or frozen tissue specimens, were 
analyzed using Incyte Genomics' cDNA microarrays (Mouse GEM 2/Unigene 1 LifeArrays 
and Human Unigene1 LifeArray) and Affymetrix oligonucleotide microarrays (MGU74A, 
MOE430 Set, HG U133 Set, or HG 1.0 ST). Mouse GEM 2/Unigene 1 arrays contained 9596 
elements corresponding to 9307 total unique genes/clusters, Human Unigene1 contained 
9182 elements representing 8472 unique genes or expressed sequence tags, and the 
MGU74A, MOE430 Set, HG U133 Set, and HG 1.0 ST arrays contained 12 654, >30 000,  
>39 000, and 28 869 genes/transcript variants, respectively. The validity of the Affymetrix 
probe sets of the genes selected for further studies were checked by BLAST searches of non-
redundant databases at the National Center for Biotechnology Information. Further, the probe 
accuracies of the arrays have been reported to be quite high (the number of sequence-verified 
probes with perfect matches ≥ 85% in the older and ≥ 95% in the newer arrays; Alberts et al. 
2007). 
 
 
3.2 Northern blot analysis (I) 
The Tβ4 mRNA levels of normal and transformed mouse fibroblasts, human melanocytes 
and melanoma cell lines, and a clinical melanoma metastasis were confirmed by Northern 
blot analysis. Hybridization with human β-actin cDNA control probe was used to check the 
uniform loading of the samples.  
 
 
3.3 RT-PCR analysis (I-IV) 
The expression levels of the identified candidate genes, various related molecules, and the 
Tβ4 antisense-RNA were confirmed by reverse transcription-PCR (RT-PCR). The primers 
and PCR conditions used are listed in Tables 4 and 5. For Tβ4 antisense-RNA, the forward 
primer was specific for the pLRT-vector and the reverse one for the Tβ4 antisense-RNA. The 
primers and PCR conditions for human β-actin, used as a loading control, were the same as 
previously described (Soikkeli et al. 2007). 
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Table 4. Primer sequences and PCR conditions used for mouse mRNAs. 
Gene name (Gene ID)  Polarity Sequence 5' to 3'         Annealing (ºC)      Cycles* 
Ctsl (NM_009984)   F ATGAGGAATTCAGGCAGGTGGTGA 56      18 
    R ACTCAGTGAGATCAGTTTGCCGGT 
Gapdh (NM_008084)  F GGGTGTGAACCACGAGAAAT  59      30 
    R GGTCCTCAGTGTAGCCCAAG 
Itgα4 (AF109136)   F AGGGTCCTTGTCGGAAGTGACAAA 58      35 
    R AGCCTGGGACCTCTTTGCCTTTAT 
Itgα6 (BC058095)   F TGGAGGTACAGTTGTTGGTGAGCA 55      20 
    R AAACACCGTCACTCGAACCTGAGT 
ItgαE (DQ386608)   F AACGGAGGGTCCTTTCTGTGTGAA 58      30 
    R GCATGTCTGAATTGAAGGCTGCGT 
Itgβ7 (BC011184)   F AGTGTGCGACTGTAACTGTGGTGA 53      23 
    R ACTCTGCACAATCCCTGTACTGCT 
Itgβ1 (BC050906)   F TCGCTGATTGGCTGGAGGAATGTA 57      20 
    R TCCTGCAGTAAGCGTCCATGTCTT 
Itgβ4 (L04678)   F AGGGAGGCTGGCTTTCAATGTAGT 55      25 
    R TTCACCAGGTGCTCAGTGTCATCA  
Tβ4 (NM_021278)  F CCTCATCCTCCTCGTCCTTA  56      30 
    R TGATCCAACCTCTTTGCATC 
Tβ4 antisense-RNA  F CCTACAGGTGGGGTCTTTCA  62      23 
    R TCGCCAGCTTGCTTCTCTTG 
Tβ10 (NM_025284)  F GTAAGAAAATGGCAGACAAGCC  50      30 
    R AGTCCGATTAGTGGAGGG 
*The numbers of cycles were optimized to be in the linear range. F = forward, R = reverse 
 
 
Table 5. Primer sequences and PCR conditions used for human mRNAs. 
Gene name (Gene ID/reference) Polarity Sequence 5' to 3'          Annealing (ºC)    Cycles* 
FN (Tavian et al. 1994)  F GGAGAGAGTCAGCCTCTGGTTCAG 56      25 
    R TGTCCACTGGGCGCTCAGGCTTGTG 
ITGβ1 (NM_002211)  F TGCGAGTGTGGTGTCTGTAAGTGT 56      30 
    R TGACCACAGTTGTTACGGCACTCT 
Tβ4 (BT007090)   F TGTCTGACAAACCCGATATGGCT  57      35 
    R GCCTGCTTGCTTCTCCTGTTCAAT 
TGFBI (NM_000358)  F TGTGTGCTGAAGCCATCGTT  61      25  
    R ACATGGACCACGCCATTTGT 
TGF-β1 (BC022242)  F ACAATTCCTGGCGATACCTCAGCA 61      25 
    R TCTTCTCCGTGGAGCTGAAGCAAT 
TGF-β2 (BC096235)  F AAACAAGAGCAGAAGGCGAATGGC 61      30 
    R CTCCAGCACAGAAGTTGGCATTGT 
TGF-β3 (BC018503)  F TGGACTTCGGCCACATCAAGAAGA 61      40 
    R TCTCCATTGGGCTGAAAGGTGTGA 
TLN1 (AF177198)   F AGGAAGCATGTGGACCTTTGGAGA 61      30 
    R TGGCAGCCAGAAGAAGTTTGCTTG  
TN-C (Katenkamp et al. 2004) F GAGATTTAGCCGTGTCTGAGGTTG 57      25 
    R AGGAGAGATTGAAGCTCTCG 
TN-C (Latijnhouwers et al. 2000) F ACCGCTACCGCCTCAATTAC  57      25 
    R GGTTCCGTCCACAGTTACCA 
*The numbers of cycles were optimized to be in the linear range. F = forward, R = reverse.  
The used FN primers amplify both EDA+ and EDA- FN mRNAs. The TN-C primers published by Katenkamp et al. (TnA4F 
and TnBR) amplify the alternatively spiced domains A4-B containing mRNAs of large TN-C isoforms and those published 
by Latijnhouwers et al. (TEN5 and TEN6) amplify TN-C mRNAs containing or not containing the A1-D domains. 
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4. PROTEIN ANALYSES (I-IV) 
 
4.1 Western blotting (I-IV) 
Whole cell lysates, serum-free conditioned media (CM), or immunoprecipitated proteins in 
1xLSB were resolved by SDS-PAGE and transferred onto nitrocellulose membrane. The 
membranes were then immunoblotted using primary antibodies detailed in Table 3 and 
horseradish peroxidase-conjugated secondary antibodies. 
 
 
4.2 Immunofluorescence staining (I-II, IV) 
Cells grown on glass coverslips were fixed with 3.5% paraformaldehyde, permeabilized with 
0.1% Triton X-100 (except for TGFBI), and immunostained with the antibodies detailed in 
Table 3. The secondary antibodies used were conjugated with TRITC, FITC, or Alexa Fluor 
488 dyes, and actin filaments were detected using Alexa Fluor 594 -conjugated phalloidin 
(Molecular Probes). Mounting was done with the Prolong Antifade Kit (Molecular Probes) or 
Vectashield H-1200 mounting medium containing DAPI (Vector Laboratories).  
 
 
4.3 Flow cytometry (II) 
The cell surface level of Itgα6 in 4N and Amdc-s cells were analyzed by flow cytometry. The 
primary antibody used was the clone GoH3 and secondary antibody was biotinylated goat 
anti-rat antibody. Finally, r-phycoerythrin-streptavidin (Vector Laboratories, Inc) was used 
for detection with the flow cytometer (FACScan; Becton Dickinson). 
 
 
4.4 Immunoprecipitation (II) 
For analysis of integrin heterodimers, Amdc-s cells were immunoprecipitated with Itgα6 
antibody (GoH3 or MA6), and the immunoprecipitates were analyzed for the existence of the 
candidate partners Itgβ1 and Itgβ4 by Western blotting. Epithelial carcinoma cell line A431 
was used as a positive control for Itgβ4. 
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4.5 Assay of cathepsin L activity (II) 
The effect of neutralizing Itgα6 antibody on cathepsin L activity was tested on Amdc-s cells 
cultured both on plastic plates and on BD BioCoat Thin Layer Matrigel dishes. The cells 
were preincubated with neutralizing Itgα6 antibody before plating and grown for 2 days in 
the presence of the antibody. The CM were then collected and concentrated (the added 
immunoglobulins were first excluded using 100 kDa filter devices), and the activity of 
secreted cathepsin L was assayed as previously reported (Ravanko et al. 2004) in the 
presence of heparin. 
 
 
 
5. TRANSFECTION EXPERIMENTS (I-II, IV) 
 
5.1 Tetracycline-inducible antisense-RNA expression vector (I) 
For tetracycline-inducible Tβ4 antisense-RNA expression, the rat Tβ4 cDNA (coding region) 
was inserted in reversed orientation into the inducible pLRT expression vector (Watsuji et al. 
1997), and the resulting pLRT-Tβ4-antisense vector was then transfected into Amdc-s and -
as cells using Lipofectamine Plus reagent (Invitrogen). To obtain stable cell lines (Amdc-s-
pLRT-Tβ4-as and Amdc-as-pLRT-Tβ4-as), blasticidin S selection was used. To study the 
effect of decreased Tβ4 protein levels, the expression of Tβ4 antisense-RNA was induced by 
the addition of doxycycline (1 μg/ml; Sigma-Aldrich). 
 
 
5.2 siRNA oligonucleotides (I-II) 
In addition to Tβ4 antisense-RNA expression, small interfering RNAs (siRNAs) were used to 
diminish Tβ4 expression. For that, two siRNAs targeted towards the mouse Tβ4 mRNA 
coding region,  as well as a negative control siRNA targeted towards a scrambled sequence 
were transfected into Amdc-s and -as cells using Oligofectamine, Lipofectamine 2000 (both 
from Invitrogen), or Fugene 6 (Roche Diagnostics GmbH) reagents. In addition, to target c-
Jun expression, siRNA oligonucleotide pool to mouse c-Jun (sc-29224) and control siRNA-A 
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(sc-37007; both from Santa Cruz Biotechnology) were transfected into Amdc-s cells using 
the same transfection reagents. 
 
 
5.3 shRNA expression vectors (II, IV) 
To target c-Jun expression with short hairpin RNA (shRNA) expression, empty 
pSuper.retro.puro vector and the c-Jun shRNA construct, kindly provided by Dr. Kazushi 
Inoue (Wake Forest University Health Sciences, Winston-Salem, NC), were transfected into 
Amdc-s cells using the above mentioned reagents. To study the effect of TGFBI knockdown 
on melanoma cells, empty pLKO.1 vector and shRNA target set for NM_000358 (TGFBI; 
both from Open Biosystems), and MISSION Non-target shRNA control vector (Sigma-
Aldrich) were transfected into WM239 cells using Lipofectamine 2000. To obtain stable cell 
lines, puromycin selection was used and the cells were cloned using the cloning cylinder 
technique. Two selected TGFBI shRNA clones, 239 G5B and 239 G6C (bearing TGFBI 
shRNA constructs G5 and G6, respectively), as well as one non-target shRNA clone 239 
nt3A and one empty vector clone 239 pLKO.1 were used in the following experiments 
(except only 239 nt3A and 239 G6C were tested in vivo). 
 
 
 
6. FUNCTIONAL ASSAYS (I-IV) 
 
6.1 Adhesion assays (II, IV) 
To study cell attachment onto coated surfaces, two assay formats were used: the 12-well plate 
format (II), and the 96-well plate format (IV). In both formats, the wells were first coated 
with the studied proteins (LN and pFN used for 12-wells; TGFBI, cFN, pFN, COL-I, COL-
IV, LN, and VN used for 96-wells), after which the cells were allowed to attach.  Fatty acid 
free, low-endotoxin BSA served as a control in both the assay formats. The quantification of 
cell attachment differed between the assay formats. In the 12-well format, the wells were 
washed once, the attached cells were trypsinized, and the cell numbers were counted with a 
Coulter particle counter (Beckman Coulter). In the 96-well format, the wells were 
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photographed after 1h 30 min (± 15 min) adhesion and the percentage of attached and spread 
cells was then calculated manually from printed images (2 replicas, 3 images from each well). 
 
 
6.2 Analysis of cell growth (I-II, IV) 
To study the proliferation rates of the cells, a fixed number of cells were added onto 12-well 
plates in triplicates, and the total number of trypsinized cells were counted at selected time 
points using a Coulter particle counter. To test the effect of latrunculin A (LAT-A) on cell 
growth (I), varying concentrations of the toxin were added to the cells 2 days after subculture. 
To test the effect of Itgα6, Itgβ1, and Itgβ7 antibodies, the antibodies were preincubated with 
the cells and included in the growth medium. 
 
 
6.3 Migration assays (I, III-IV) 
Cell migration was tested using the traditional scratch wound assay (I), three-dimensional 
(3D) collagen gel assay (I, III-IV), and Boyden chamber assay (IV). To study the effect of 
LAT-A using scratch wound assay, 80-90% confluent cell cultures were wounded using 
sterile pipette tips and cell migration into the wound area was then followed by microscopy 
for 24 h in the presence or absence of LAT-A. In 3D-collagen gel assays, the cells were cast 
between two COL-I gel layers, covered with growth medium (LAT-A, when studied, was 
included in this medium; TN-C and FN were added into the upper gel layer and the growth 
medium) and followed for several days by microscopy. In Boyden chamber assays, the 
chambers were first coated with COL-I on both sides of the membrane, and migration of the 
cells from the upper compartment (serum-free medium) into the lower compartment (10% 
serum) was quantitated by crystal violet staining, photography, and manual counting from 
printed images. 
 
 
6.4 Invasion assays (I-II, IV) 
Cell invasiveness in vitro was analyzed using thick gels of Growth Factor Reduced Matrigel 
(BD Biosciences), where the cells were cast between two Matrigel layers. To see the effect of 
LAT-A on cell invasion, it was included in the Matrigel layers and the uppermost growth 
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medium. Neutralizing antibodies were, in turn, preincubated with the cells and included into 
the Matrigel layers. The invasive growth of the cells in the matrix was then followed by 
microscopy for one week. To see the effect of TGFBI knockdown on melanoma cell invasion 
in vivo, 3 x 106 TGFBI-KD cells (239 G6C) or non-target shRNA control cells were injected 
subcutaneously (diluted 1:1 with 75 µl Growth Factor Reduced Matrigel) into Balb/c nu/nu 
mice (6 animals per group, one tumor per animal). Animal protocols were approved by the 
Experimental Animal Committee of the Provincial Government of Southern Finland. Tumor 
growth was monitored thrice a week using calipers, and the mice were euthanized after 30 
days. The tumors, lungs, livers and lymph nodes (one per animal) were removed and 
embedded in paraffin or frozen in liquid nitrogen (two tumors per group). 
 
 
 
7. IMMUNOHISTOCHEMISTRY (II-IV) 
Tissue sections were cut at 5 μm thickness and deparaffinised, and antigen retrieval was 
accomplished by heating in microwave oven, except for FN, TN-C, and PCOL-I staining, 
where the samples were treated with trypsin. Endogenous peroxidase activity was then 
blocked and the sections were incubated with the primary antibodies detailed in Table 3 at 
4°C overnight. The immunoreactivity was detected by processing with the 
StreptABComplex/HRP Duet kit, the chromogen being either 3,3'-diaminobenzidine (DAB) 
or 3-amino-9-ethylcarbazole (AEC). Finally, the sections were gently counterstained with 
Harris or Mayer’s Hematoxylin (Polysciences Inc) and mounted. In immunohistochemical 
analysis of melanoma tumors, the tumors were semi-quantitatively scored as −, +, ++, or +++ 
corresponding to absent, weak, moderate and strong/very strong immunoreactivity, 
respectively. This quantification was made double blindly. Correlative analyses of the data 
were done by chi-square tests. 
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RESULTS AND DISCUSSION 
 
1. MICROARRAY ANALYSES (I-IV) 
 
1.1 Incyte Genomics versus Affymetrix arrays (I-IV) 
To identify molecules potentially related to the invasiveness of fibrosarcomas and 
melanomas, we first compared the gene expression profiles of the studied 
transformed/malignant cells and the corresponding normal cells using two different 
microarray platforms: cDNA (Incyte Genomics' LifeArrays) and oligonucleotide (Affymetrix 
GeneChips) arrays. Two platforms were used to make the results more confident, an idea that 
has been validated in a previous study (Lee et al. 2003). Incyte Genomics’ analyses 
comprised competitive hybrization of two differently fluorescently labeled RNA samples to 
cDNA fragments (average length 1000 bp) printed onto glass slides, whereas Affymetrix 
analyses are based on two independent hybridizations of biotinylated cRNA samples to glass-
immobilized oligonucleotides (25mers) synthesized in situ, and fluorescent detection using 
antibody amplification. 
 
With both the platforms used, the highest changes were quite similar (I: Tables 1 and 2; Table 
6 and IV: Supplemental Table 1). As expected, the differing gene contents of the arrays 
resulted in some differences in the lists of the topmost changes, one example being 
transforming growth factor beta-induced (further studied in IV), which was only present in 
Affymetrix’ arrays. Also, the exact fold change values expectedly varied between the two 
analysis methods (see II), but the topmost changes detected with both of the systems usually 
nicely confirmed each other in terms of being markedly changed in both. As the fold changes 
in repeated analyses using the same method also showed variation (one reason being 
biological variation), it is advisable not to concentrate too much on the exact fold changes. 
The Incyte Genomics' competitive system was still applicable with this small number of 
samples, but for more extensive studies, the Affymetrix non-competitive platform is more 
useful.
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1.2 Mouse fibrosarcoma cells (I-II) 
To study the gene expression changes behind the high invasiveness of mouse Amdc-s and -as 
fibrosarcoma cells, we compared their gene expression patterns with that of the empty vector-
bearing 4N cells. The results (I: Tables 1 and 2) revealed the gene expression patterns of 
Amdc-s and -as cells to be surprisingly similar even if the former was transformed by 
overexpression and the latter by blockage of the expression of the same gene, S-
adenosylmethionine decarboxylase (AdoMetDC). This result was, however, in concert with 
their similar, transformed phenotype. As we also analyzed an exceptionally aggressive clone 
of Amdc-as cells, we could study the effect of the degree of transformation on the gene 
expression levels. Thymosin β4, as an example, showed 14.0-fold up-regulation in the pool of 
Amdc-as cells (26.4 and 20.6 in pools of Amdc-s cells), whereas it showed 62.2-fold up-
regulation in an extremely aggressive clone (I: Table 1). Similarly, integrin β7 showed 6.5-
fold up-regulation in the pool of Amdc-as cells (8.4 and 8.2 in pools of Amdc-s cells), and 
22.4-fold up-regulation in the aggressive clone (I: Table 1). Thus, the fold change values 
obtained greatly correlates with cell aggressiveness. 
 
The highest gene expression changes potentially relevant for the high invasiveness of Amdc-s 
and -as cells included thymosin β4, encoding an actin-sequestering protein related to cell 
motility (the highest up-regulation with both the platforms), cell surface adhesion molecules 
encoding integrin α6, integrin β7, and protocadherin 7 (all increased), ECM 
components/modifiers encoding cathepsin L, chondroitin sulfate proteoglycan 2, decorin, 
matrix metallopeptidase 2 (type IV collagenase), hyaluronan synthase 2, ECM-associated 
protein Sc1, osteopontin (all increased), and procollagen type I α1, microfibrillar-associated 
protein 5, and thrombospondin 1 (all decreased). Of these, the cysteine proteinase cathepsin L 
has been previously shown to be the major secreted protein of Amdc-s cells and to play a 
major proteolytic role in the invasiveness of these cells (Ravanko et al. 2004). In subsequent 
studies, we concentrated on studying the function of the actin cytoskeleton-related molecule 
thymosin β4 (Tβ4), and the adhesion molecules integrin α6 (Itgα6) and integrin β7 (Itgβ7) in 
Amdc-s and -as cell invasion. Further, we studied the presence and localization of Tβ4, 
ITGα6, and cathepsin L in human sarcoma specimens by immunohistochemistry (see below). 
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1.3 Human melanoma cells (III-IV) 
To study the invasion/progression-related gene expression changes in melanoma cells, we 
analyzed the gene expression patterns of two melanoma cell lines, vertical growth phase 
(VGP) WM793 cells and metastatic WM239 cells, as compared to those of two primary 
cultures of melanocytes, 42V and Mela3 (Table 6 and IV: Supplemental Table 1). The gene 
expression patterns of the studied melanoma cells verified many of the known melanoma-
related changes, reported for instance in an analysis of multiple melanoma cell line 
microarray studies utilizing the same Affymetrix HG-U133A arrays (Hoek 2007). However, 
some changes not reported in that study were also identified. The reason for this discrepancy 
may be the varying characteristics (e.g. invasiveness) of the studied cell lines, as in Hoek’s 
analysis only genes showing up/down-regulation in all the studied cell lines were included in 
the results. First, both the studied melanoma cell lines showed decreased expression of the 
gene encoding the cell-cell adhesion molecule E-cadherin, a change that allows melanoma 
cells to lose adhesive interactions with keratinocytes and become more migratory and 
invasive (Satyamoorthy and Herlyn 2002; Lee and Herlyn 2007). Consistently, both cell lines 
also showed up-regulation of N-cadherin (2.2- and 3.3-fold changes, respectively, with 
Affymetrix arrays) helping them to interact with dermal fibroblasts and endothelial cells 
(Satyamoorthy and Herlyn 2002). Similarly to E-cadherin, the melanocyte-keratinocyte 
interaction molecule encoding P-cadherin (Rickelt et al. 2008), was found to be down-
regulated in both the cell lines. Further, up-regulated expression of the desmosomal cadherin 
encoding desmoglein 2, previously reported in some melanomas (Rickelt et al. 2008), was 
detected in both the cell lines (8.0 and 7.3, respectively, with Affymetrix arrays). 
 
Besides E- and P-cadherins, the shared down-regulated genes in the studied amelanotic 
WM793 and WM239 cells (ceased to produce the pigment melanin) included melanin 
synthesis related molecules encoding silver homolog (mouse), melan-A, tyrosinase, 
microphthalmia-associated transcription factor, and oculocutaneous albinism II. Further, 
both cell lines showed down-regulated expression of the genes encoding serine protease 
dipeptidyl-peptidase 4 [whose down-regulation has previously been found to be an important 
early event in melanoma pathogenesis (Van den Oord 1998; Wesley et al. 1999)], a 
nucleotide modifying enzyme guanosine monophosphate reductase, an actin-regulatory 
molecule capping protein (actin filament), gelsolin-like, and a cation channel melastatin 1 
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[10.4- and 9.8-fold changes with Affymetrix arrays; whose loss of expression has previously 
been found to correlate with melanoma aggressiveness (Duncan et al. 1998)]. 
 
In addition to the up-regulated expression of the cell-cell adhesion molecules encoding N-
cadherin and desmoglein 2, WM793 and WM239 cells showed up-regulated expression of 
genes encoding the ECM modification related molecules matrix metallopeptidase 1 [also 
known as collagenase-1; the highest increase in both cell lines using Affymetrix arrays; 
expression previously reported to correlate with melanoma invasion and rapid progression 
(Airola et al. 1999; Nikkola et al. 2002)], procollagen C-endopeptidase enhancer, cathepsin 
C (6.3- and 6.1-fold changes with Incyte Genomics’ arrays), and tissue inhibitor of 
metalloproteinase 3 (11.8- and 5.7-fold changes with Affymetrix arrays). Further, both the 
cell lines showed up-regulated expression of the cell adhesion molecules encoding 
thrombospondin 1, integrin α4, integrin α6 (4.8- and 3.8-fold changes with Incyte Genomics’ 
arrays), and integrin β3 (10.5- and 14.5-fold changes with Affymetrix arrays), as well as 
integrin activity modulating protein melanoma inhibitory activity. Further, the cell lines were 
found to show increased expression of genes encoding various mitogens (and their function 
modulating proteins), chemokines, and cytokines, such as connective tissue growth factor, 
platelet-derived growth factor α (11.5- and 15.4-fold changes with Affymetrix arrays), 
transforming growth factor α, interleukin 8, monocyte chemotactic protein (9.6- and 3.6-fold 
changes with Affymetrix arrays), and insulin-like growth factor binding proteins 2 and 3. 
Interestingly, the cell lines also showed overexpression of the angiogenesis-related molecules 
encoding cysteine-rich angiogenic inducer 61, vascular endothelial growth factor A, 
neuropilin-1 (6.4- and 5.4-fold changes with Affymetrix arrays), and angiopoietin 1 (2.3- and 
2.1-fold changes with Affymetrix arrays). One more, interesting gene, encoding an inhibitor 
of retinoic acid signaling, preferentially expressed antigen in melanoma (7.7- and 24.3-fold 
changes with Affymetrix arrays) showed up-regulation. In line with previous studies (Hoek et 
al. 2004; Hoek 2007; Degenhardt et al. 2010), major histocompatibility complex (MHC) class 
II molecules (especially DR α), normally expressed in antigen presenting cells, were also 
found to be up-regulated in both the cell lines. As reported by Degenhardt et al. (Degenhardt 
et al. 2010), the metastatic cells (WM239) most often showed lower expression of MHC class 
II molecules than the VGP cells (WM793). 
 
Moreover, besides the above mentioned shared changes, the VGP WM793 cells also showed 
increased expression of the proteoglycan lumican encoding gene. Metastatic WM239 cells, in 
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turn, additionally showed increased expression of the genes encoding ECM modifying 
proteases matrix metallopeptidase 15 (also known as membrane-type 2 MMP; 4.1-fold 
change with Affymetrix arrays) and matrix metallopeptidase 8 [6.6-fold change with 
Affymetrix arrays; high serum levels found to correlate with melanoma ulceration and 
vascular invasion (Vihinen et al. 2008); wild type protein shown to inhibit melanoma 
progression, but inactivating mutations often found in melanoma tumors (Palavalli et al. 
2009)], ECM component collagen type XV, α1 (20.4-fold change with Affymetrix arrays), 
angiogenic mitogen pleiotrophin (3.5-fold change with Affymetrix arrays), and cytokine 
macrophage-specific colony-stimulating factor (3.8-fold change with Affymetrix arrays). As 
most of these “cell line specific” changes (apart from matrix metallopeptidase 8) were not 
included in the Hoek’s list of changes typical to melanoma (Hoek 2007), they appear not to 
represent universal melanoma-related changes, but may be related to metastatic alterations. 
 
In addition to the above mentioned cell adhesion and ECM modification-related molecules, 
WM793 and WM239 cell lines interestingly showed increased expression of various ECM 
components, including fibronectin 1 (FN) and tenascin-C (TN-C) (being the most highly up-
regulated ECM proteins with both microarray platforms), as well as collagen type IX, α3 (9.0- 
and 16.4-fold changes with Affymetrix arrays), consistent with a previous study (Hoek et al. 
2004). One additional interesting ECM protein, transforming growth factor beta-induced 
(TGFBI), was also among the highest up-regulated genes using Affymetrix arrays (2nd highest 
in WM239 cells; 108th highest in Hoek’s analysis). In subsequent studies, we concentrated on 
studying the role of the cell adhesion-related molecules TN-C, FN, and TGFBI in melanoma 
cell invasion and melanoma progression. 
 
 
1.4 Fibrosarcoma versus melanoma (I-IV) 
As predicted from the different origins of fibrosarcoma and melanoma cells, the gene 
expression patterns of AdoMetDC-transformed cells and melanoma cells were quite different, 
especially the topmost changes. Among the changes in common were, however, up-regulated 
expression of integrin α6 and TN-C (2.5- and 2.0-fold changes in Amdc-s and -as cells as 
analyzed with Incyte Genomics’ arrays). Interestingly, TGFBI was found to show up-
regulated expression only in the extremely aggressive clone of Amdc-as fibrosarcoma cells 
(6.8-fold change with Incyte Genomics’ array), which is consistent with the previous studies 
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reporting elevated TGFBI expression to be related to the aggressiveness of the tumor 
(Zajchowski et al. 2001; Sasaki et al. 2002; Ma et al. 2008). 
 
In addition to the shared gene expression changes between fibrosarcoma and melanoma cells, 
a few genes showing contrasting behavior were identified. They included e.g. cysteine-rich 
protein 61 (Cyr61), thrombospondin 1, and protease, serine, 23, which were down-regulated 
in Amdc-s and -as cells, but up-regulated in the studied melanoma cells (14.6- and 4.4-fold 
changes in WM793 and WM239 cells with Affymetrix arrays). Of these, Cyr61 has 
previously been shown to induce apoptosis of fibroblasts, but to promote the survival of 
endothelial cells (Todorovicc et al. 2005), so the difference in its expression levels is 
understandable and can indeed be cell type-specific. Also the angiogenesis inhibitor 
thrombospondin-1 has been reported to show varying expression levels in different cancers. 
Protease, serine, 23 (also known as SPUVE), in turn, is still a poorly studied ovarian protease 
which has been found to be overexpressed in papillary thyroid carcinomas (Huang et al. 
2001). 
 
 
 
2. FUNCTIONAL CHARACTERIZATION (I-IV) 
 
2.1 Thymosin β4 (I) 
Tβ4 is a strongly polar 5 kDa polypeptide that functions as a major actin sequestering 
molecule (see the section “Actin polymerization”). Tβ4 sequesters a large pool of monomeric 
actin (G-actin) by forming a 1:1 complex with it, and from this pool, the actin monomers can 
then be easily released for the rapid polymerization of actin filaments (F-actin). Interestingly, 
previous reports have shown up-regulated expression of Tβ4 in various cancer cell lines and 
human tumors (Hall 1991; Yamamoto et al. 1993; Santelli et al. 1999; Xie et al. 2002), and  
in functional studies, increased Tβ4 expression has been related to increased tumorigenicity 
and metastatic potential (Clark et al. 2000; Kobayashi et al. 2002; Cha et al. 2003; Ji et al. 
2003; Wang et al. 2003; Wang et al. 2004;). Based on these data and the highly up-regulated 
expression, we decided to study the possible role of Tβ4 in the high invasiveness of 
AdoMetDC-transformed cells. 
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2.1.1 Tβ4 is overexpressed in Amdc-s, Amdc-as, and E4 fibrosarcoma cells 
The highly up-regulated expression of Tβ4 in Amdc-s and -as cells was first verified with 
Northern blotting (I: Fig. 1A) and RT-PCR (data not shown). In addition to these cells, a 
marked up-regulation of Tβ4 was detected in ras-tranformed mouse fibroblasts (E4; I: Fig. 
1A) and the metastatic WM239 melanoma cells (I: Fig. 1C). Additionally, the change at the 
protein level was confirmed in fibrosarcoma cells by immunofluorescence staining (I: Fig. 
1D). 
 
 
2.1.2 Tβ4 overexpression is related to the transformed phenotype 
In line with the role of Tβ4 as a G-actin reservoir, the Tβ4-overexpressing cells were found to 
show distinctive actin staining pattern as compared to 4N cells (Fig. 3). Previously, our group 
has shown that activation of the proto-oncogene c-jun, a member of the dimeric activator 
protein 1 (AP-1) transcription factor complex, is required for AdoMetDC-induced 
transformation and expression of a dominant-negative mutant of c-Jun (TAM67), inhibiting 
the function of c-Jun, is able to reverse the transformed phenotype (Paasinen-Sohns et al. 
2000; II). Here, we also analyzed the Tβ4 expression levels of Amdc-pLRT-TAM67 cells 
before and after TAM67-induced reversal of transformation, and found them to be clearly 
regulated by c-jun (I: Fig. 1B). Tβ4 expression level did not, however, decrease back to the 
level of control 4N cells upon TAM67 induction, indicating the existence of other regulatory 
molecules as well. 
 
 
 
Figure 3. The staining patterns of actin filaments in 4N (a), Amdc-s (b), and ras-tranformed E4 cells 
(c), as detected with Alexa Fluor 594 -conjugated phalloidin. Note the areas of highly concentrated 
actin filaments (containing pseudopodia-like structures) at the edges of the migratory Amdc-s and E4 
cells (b and c). Exposure time 4000ms in a and 2000ms in b and c. 
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To study the effects of Tβ4 overexpression in AdoMetDC-transformed cells, we blocked its 
expression by inducible antisense-RNA expression or addition of siRNAs (inducible 
antisense-RNA shown in I: Fig. 2A). This expression knockdown led to reversion of the 
transformed morphology and impaired dispersion/migration of the cells in three-dimensional 
(3D)-collagen gel (I: Fig. 2B-C). The degree of morphological reversion, however, varied, 
and the effect tended to weaken over an extended time period, indicating that some 
compensatory mechanism may be operational. 
 
 
2.1.3 LAT-A, an inhibitor of Tβ4, affects the morphology and growth of Amdc-s 
and -as cells 
Latrunculin A (LAT-A; structure shown in Fig. 4) is a sponge toxin shown to inhibit the 
binding of Tβ4 to actin (Yarmola et al. 2000). LAT-A binds G-actin at 1:1 stoichiometry, 
similarly to that of Tβ4, and thereby inhibits actin polymerization (Spector et al. 1983; Coue 
et al. 1987). When Amdc-s and -as cells were exposed to this toxin (0-350 ng/ml), their 
morphology changed in a concentration- and time-dependent manner into ball-and-stick 
model-looking cells with a round center and thin protrusions (I: Fig. 3C-F). With high 
concentrations or prolonged periods of exposure, the cells finally detached and become 
swollen, probably due to impaired cytokinesis. No activation/cleavage of caspase-3, 
indicating apoptosis, was detected in these detached cells by immunoblotting. The 
morphological effect of LAT-A on these cells was reversible after a short exposure, but after 
a longer exposure of high concentration (350 ng/ml for 2 days or longer) the cells did not 
recover fully, and many of the cells had multiple nuclei (implying impaired cytokinesis as 
well) (I: Fig. 3G-H). In contrast to Tβ4-overexpressing cells, normal fibroblasts were quite 
resistant to LAT-A’s morphological effect (I: Fig. 3A-B). 
 
In addition to the morphological effect, LAT-A selectively inhibited the growth of Amdc-s 
and -as cells as compared to that of 4N cells (I: Fig. 4). Even with only 50 ng/ml LAT-A (half 
of the concentration used for morphological effects), the growth of Tβ4-overexpressing cells 
was seriously inhibited. As the untreated 4N and Amdc-s cells showed similar growth rates, 
Tβ4 overexpression itself does not confer any growth advantage to these transformed cells. 
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Figure 4. The structure of LAT-A, a macrolide 
isolated from the Red Sea sponge Negombata 
magnifica (formerly Latrunculia magnifica). 
The sponge uses this toxin to defend itself 
from hungry fishes. Modified from Morton et al. 
2000. 
 
 
2.1.4 LAT-A impairs the migration of Amdc-s, Amdc-as, and E4 cells 
As reorganization of the actin cytoskeleton is important for cell migration, we also tested the 
effect of LAT-A on cell motility. In routine cell culturing we had noticed Amdc-s and -as 
cells to be more migratory than control 4N cells. As anticipated, the toxin clearly affected the 
migration of both Amdc-s and -as cells, as well as that of Tβ4-overexpressing E4 cells (ras-
transformed fibroblasts), when analyzed by scratch wound closure proliferation/migration 
assay (Amdc-s shown in Fig. 5), commonly used to assess the effects of drugs, or 3D-
collagen gel assay (data not shown). Again, the toxin had a milder effect on control 4N cells 
showing lower Tβ4 expression. 
 
 
2.1.5 LAT-A blocks the invasion of Amdc-s and -as cells in Matrigel 
Matrigel matrix is a basement membrane extract from mouse sarcoma tumor, consisting 
mainly of LN, COL-IV, entactin, and heparan sulfate proteoglycan.  Matrigel allows the 
reconstitution of 3D-ECM around tumor cells in vitro, mimicking the situation in vivo. 
Amdc-s and -as cells normally grow and invade well in this ECM matrix, being more 
invasive than human HT-1080 fibrosarcoma cells, MDA-MB-231 breast cancer cells 
(Ravanko et al. 2004), or ras-oncogene-transformed fibroblasts (E4; Paasinen-Sohns et al. 
2011). When Amdc-s and -as cells were grown in 3D-Matrigel matrix in the presence of 
LAT-A, their invasion was dramatically inhibited (I: Fig. 5A-C). Even with a concentration 
of 50 ng/ml, the invasion was effectively impaired, and with a concentration of 100 ng/ml it 
was totally inhibited. In addition, LAT-A was also able to block Amdc-s and -as cell invasion 
when added to already formed invasive colonies, and even seemed to shrink the existing 
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colonies (I: Fig. 5F-H). The growth of the control, noninvasive 4N cells was, as expected, not 
affected by LAT-A (I: Fig. 5D-E). 
 
 
 
 
Figure 5. Scratch wound assay comparing the migration of control 4N cells and Tβ4-overexpressing 
Amdc-s cells in the absence and presence of LAT-A (25 ng/ml). 
 
 
2.1.6 Tβ4 shows strong immunostaining in Amdc-s-induced mouse 
fibrosarcomas 
To study the distribution of Tβ4 in tissue specimens, Amdc-s-induced murine fibrosarcomas 
and human sarcoma specimens (n = 10) were analyzed by immunohistochemistry (IHC). In 
normal mouse tissues, high Tβ4 immunostaining was detected especially in hair follicles 
(Fig. 6a), whereas in the induced fibrosarcomas, the immunoreactivity was found scattered 
around the tumor (Fig. 6b). Further, high-grade human sarcomas were found to show intense 
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Tβ4 immunostaining (Fig. 6c and 7b). These data thus support the idea of Tβ4 as a potential 
target for cancer therapy. 
 
 
 
Figure 6. Amdc-s cell-induced mouse fibrosarcomas and human sarcomas show intense Tβ4 
immunostaining. a) Normal mouse tissue, b) Amdc-s cell-induced tumor tissue, and c) undifferentiated 
pleomorphic human sarcoma. Magnification 400x. 
 
 
Our study was the first to show that a small-molecular toxin interfering with Tβ4 binding to 
actin can selectively inhibit cancer cell invasion. Two years later, El Sayed et al. (Sayed et al. 
2008) reported that LAT-A shows anti-invasive activity against highly metastatic human 
prostate cancer cells in vitro, and, interestingly, suppress hypoxia-induced HIF-1 activation in 
breast tumor cells. Three years after our work, Konishi et al. (Konishi et al. 2009) further 
demonstrated the ability of LAT-A to inhibit the dissemination of cancer cells in vivo 
(peritoneal dissemination of human gastric cancer in mice). Notably, no major side-effects 
were observed in the mice after intraperitoneal injection of LAT-A. Still more recently, 
Khanfar et al. (Khanfar et al. 2010) have shown LAT-A derivatives to be even more potent 
than the parental molecule in inhibiting breast cancer cell invasion. Taken together, these data 
strongly encourage testing LAT-A-like molecules for the treatment of Tβ4-overexpressing 
tumors showing high invasive and metastatic potentials. 
 
 
 
2.2 Integrins α6 and β7 (II) 
Integrins (ITGs) are the major cell surface receptors mediating adhesion to ECM molecules, 
being, at the same time, the major migration-mediating receptors (see the section “Cell-
matrix interactions”). Integrins are heterodimeric molecules, consisting of one α and one β 
subunit, and the subunit composition specifies their ligand specificity (e.g. FN, LN, COL, and 
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VN). Integrin α6 subunit (ITGα6) can dimerize with subunits β1 and β4, and both the 
heterodimers function as laminin receptors. Of these partners, integrin β1 is universally 
expressed, whereas the β4 subunit is mainly expressed in epithelial cells. The leukocyte-
specific integrin, integrin β7, in turn, can pair with subunits α4 and αE. The resulting 
heterodimers show specificity to FN, the vascular addressins MAdCAM-1 and VCAM-1 
(α4), and E-cadherin and LEEP-CAM (αE). High ITGα6 expression has previously been 
reported in several epithelial cancers, including high-grade breast carcinomas (Friedrichs et 
al. 1995) and invasive oral squamous cell carcinomas (Shinohara et al. 1999). ITGβ7 up-
regulation, in turn, has been reported in multiple myelomas and T cell lymphomas (Hurt et al. 
2004; Morito et al. 2006). As cell adhesion is one of the processes essential to cancer cell 
invasion, we further concentrated on studying the importance of the up-regulated integrins α6 
and β7 in the invasiveness of Amdc-s cells. 
 
 
2.2.1 Itgα6 and Itgβ7 are up-regulated in Amdc-s, Amdc-as, and E4 
fibrosarcoma cells 
The up-regulated expression of Itgα6 and Itgβ7 was verified in Amdc-s cells by RT-PCR 
analysis (II: Fig. 2a’) and confirmed at protein level by immunofluorescence staining (II: Fig. 
2b’), flow cytometric analysis (II: Supplementary Fig. 2A), and Western blotting (II: 
Supplementary Fig. 2B). In addition, increased expression of both genes was found in ras-
transformed E4 cells, and that of ITGα6 was found in human WM793 and WM239 melanoma 
cells, and HT-1080 fibrosarcoma cells (data not shown). Both Itgα6 and Itgβ7 expression and 
immunostaining were decreased in Amdc-pLRT-TAM67 cells upon TAM67 induction (II: 
Fig. 2a’ and c’), showing that c-Jun is also able to regulate the expression of Itgα6 and Itgβ7, 
in addition to Tβ4. 
 
 
2.2.2 Itgα6β1 mediates the binding of Amdc-s cells to laminin 
To find out the main dimerization partner of Itgα6 in Amdc-s cells, we did 
immunoprecipitation experiments. Of the two known dimerization partners, β1 and β4 
subunits, we found Itgβ1 to be the principal partner of Itgα6 in these cells (II: Fig. 4a’). In 
further studies, function blocking antibodies specific to either Itgα6 or Itgβ1 inhibited the 
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binding of Amdc-s cells to laminin and Matrigel (consisting mainly of laminin) (II: Fig. 4b’-
d’). With the antibody specific to Itgβ1 the inhibition was total and longer lasting, probably 
due to the numerous dimerization partners of β1 (more than ten). 
 
We could not solve out the main dimerization partner of Itgβ7 by immunoprecipitation. 
However, by RT-PCR we found Amdc-s cells to express ItgαE, but not Itgα4 (data not 
shown). Further, we did not find Itgβ7 antibody to inhibit Amdc-s cell binding to fibronectin 
(ligand of Itgα4β7). Despite our failure in identification of the partner and its function, to our 
knowledge, this is the first study to associate increased Itgβ7 level with the transformed 
phenotype of non-leukocytic cells. Similarly to those of Tβ4 and Itgα6, the expression of 
Itgβ7 was found to be regulated by c-Jun in Amdc-s cells (II: Fig. 2a’ and c’). 
 
 
2.2.3 Itgα6β1 is relevant for the invasion of Amdc-s cells and human HT-1080 
fibrosarcoma cells in Matrigel 
The possible role of Itgα6β1 in the high invasiveness of Amdc-s cells was tested in 3D-
Matrigel assays, mimicking the tumor-surrounding ECM. Importantly, both the Itgα6 and 
Itgβ1 antibodies effectively inhibited the invasion of Amdc-s cells, as well as human HT-
1080 fibrosarcoma cells, in this laminin-rich matrix (II: Fig. 5a’-b’). Both the used antibodies 
thus show potential for the treatment of ITGα6β1-utilizing, invasive tumors. As ITGα6 has 
many fewer dimerization partners than ITGβ1, ITGα6 specific antibodies (or their 
derivatives) could show less unwanted side-effects than the more studied ITGβ1 antibodies. 
As cancer cells are known to develop resistance to various therapies, ITGα6 antibodies could 
be used in combination with Tβ4 inhibitors and cathepsin L inhibitors [previously shown to 
be the major protease related to Amdc-s cell invasiveness (Ravanko et al. 2004)], in the 
treatment of fibrosarcomas/sarcomas overexpressing these molecules. The neutralizing 
ITGα6 antibody was not found to affect the expression or activity of cathepsin L, but the two 
molecules seem to function independently (II: Supplementary Fig. 4). 
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2.2.4 ITGα6 localizes into the invasion fronts of human high-grade 
fibrosarcomas 
To survey the clinical relevance of ITGα6 overexpression in human tumors, we analyzed by 
IHC a preliminary set (n = 24) of human fibrosarcomas and other soft-tissue sarcomas. 
Interestingly, ITGα6 showed faint to moderate staining in low-grade tumors, whereas a 
strong staining was detectable in high-grade tumors, especially in the invasion fronts (II: Fig. 
5c’ and Supplementary Fig. 5). This is in line with a previous IHC study on soft tissue 
sarcomas (not involving fibrosarcomas; Benassi et al. 1998). Interestingly, this broader study 
of Benassi et al. further reported ITGα6 expression levels to show positive correlation with 
the occurrence of metastases in the sarcoma types studied, and thus to show prognostic 
potential. Similarly, in invasive breast carcinomas, high ITGα6 expression has been reported 
to correlate with reduced survival (Friedrichs et al. 1995). When ITGα6 immunostaining was 
compared to those of Tβ4 and cathepsin L, somewhat similar patterns were detected in the 
tumors, especially with ITGα6 and Tβ4 (Fig. 7). The idea of combinatory therapy might thus 
be rational. When compared to c-Jun immunostaining, ITGα6 immunoreactivity was found to 
correlate best with the activated, phosphorylated form of c-Jun (II: Supplementary Fig. 6). 
 
 
 
Figure 7. Immunostaining of ITGα6 (a; published in II: Fig. 5c’ c), Tβ4 (b), and cathepsin L (c) in a 
high-grade (G4) fibrosarcoma. Note that cathepsin L, a secreted molecule, shows a somewhat 
different pattern of staining. Magnification 400x. 
 
 
 
2.3 Tenascin-C and fibronectin (III) 
TN-C (originally hexabrachion) and FN are large disulfide-linked ECM glycoproteins 
functioning in cell-matrix adhesion (see the section “Extracellular matrix molecules”). Of 
these, FN is an adhesive protein, whereas TN-C is able to function anti-adhesively for 
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melanoma cells, and even to affect their binding to FN (Herlyn et al. 1991). In addition to 
interacting with each other, TN-C and FN are able to interact with other ECM molecules and 
cell surface integrins. Previously, both increased TN-C and FN expression (Clark et al. 2000; 
Hoek et al. 2004) and secretion (Herlyn et al. 1991) have been reported in melanoma cells. 
We were, however, interested to study the localization of these highly up-regulated ECM 
molecules in melanoma tissue specimens and to clarify their functional role in melanoma cell 
invasion. 
 
 
2.3.1 TN-C and FN are overexpressed in WM793 and WM239 melanoma cells 
and primary melanomas 
The highly up-regulated expression of TN-C and FN in the VGP WM793 and metastatic 
WM239 melanoma cells was first verified using RT-PCR analyses (Fig. 8A), and an increase 
in secreted protein levels was confirmed by Western blotting (Fig. 8B). Adult skin fibroblasts 
were also found to express FN, but not TN-C (Fig. 8A). Further, microarray analyses of 
primary melanoma tissue specimens, compared to benign melanocytic nevi, showed 
increased expression of TN-C and FN (III: Fig. 1B). 
 
 
2.3.2 TN-C and FN show intense immunostaining in fibrillar structures 
surrounding invasive melanoma cells in tumor tissues 
To see the distribution and clinical relevance of TN-C and FN overexpression in melanoma, 
these molecules were immunohistochemically analyzed from benign nevi (n = 32), primary 
melanomas (n = 101), and clinically detected melanoma metastases (macrometastases; n = 
19). In normal skin and benign nevi, TN-C immunostaining was detected as a thin rim at the 
basement membrane (III: Fig. 2A) and surrounding blood vessels (III: Fig. 2B). Horizontally 
growing primary melanomas additionally showed very faint TN-C immunostaining in the 
immediate vicinity of the basal lamina (III: Fig. 2B). However, of the primary melanomas 
and melanoma metastases studied, strong TN-C staining was detected in 59% and 58% of the 
specimens, respectively (III: Table 1). Most importantly, in invasive VGP primary nodular 
melanomas and melanoma metastases, TN-C staining revealed strong, elongated strands and 
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ring structures surrounding melanoma cell nests and rows, particularly at the sites of invasion 
(III: Fig. 2C-D, Fig. 3A-E, Supplementary Fig. 1A and E, Supplementary Fig. 2). 
 
 
 
 
Figure 8. Confirmation of FN and TN-C up-regulation in WM793 and WM239 melanoma cells. A) RT-
PCR and B) Western blotting of secreted proteins (10 µg/lane). The antibody NCL-FIB detects FN, 
whereas BC-24 is specific for TN-C. Specificity of the used antibodies (later used in IHC) is shown in 
C), using Western blotting of purified TN-C, FN, and COL-I proteins (2 µg/lane). 
 
 
Further, in analysis of several serial sections, these invasion-associated fibrillar networks 
seemed to form tubular structures around the melanoma cells. Occasionally also red blood 
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cells were detected inside these tubules (III: Supplementary Fig. 1E). In addition to 
promoting invasion, these structures might thus aid, purposely or not on purpose, the survival 
and haematogenous spreading of the tumor cells. Interestingly, FN immunoreactivity was 
invariably found to co-localize with TN-C staining in these structures (III: Fig. 5A-B), 
suggesting that the interaction of these two molecules is important in melanoma progression. 
In benign nevi, FN was only detectable in the basal laminae of the epidermis and blood 
vessels (III: Fig. 5E). 
 
In addition to TN-C and FN, highly up-regulated expression of the ECM proteins collagen 
type I, α1 and collagen type I, α2 was detected in microarray analyses of melanoma lymph 
node metastases compared to normal lymph nodes (III: Fig. 1C). The studied WM793 and 
WM239 cell lines, in turn, were not found to express high levels of COL-I, which is expected, 
as COL-I is known to be mainly synthesized by fibroblasts and myofibroblasts. When studied 
by IHC, immunoreactivity to procollagen-I (PCOL-I), the precursor molecule of COL-I and 
an indicator of newly synthesized collagen, was found to co-localize with TN-C and FN 
staining in the fibrillar structures surrounding the invading melanoma cells (III: Fig. 6B-D). 
PCOL-I staining of these structures was, however, more variable than that of TN-C and FN, 
and PCOL-I was also detected intracellularly in the neighboring stromal fibroblasts. In 
benign nevi, PCOL-I immunoreactivity was restricted to the basal laminae (III: Fig. 6A). 
 
 
2.3.3 TN-C and FN stimulate the migration of melanoma cells in 3D-collagen-I 
To clarify the functional role of secreted TN-C and FN in melanoma cell invasion, the effect 
of purified TN-C and FN proteins on the behavior of primary melanoma cells (PMEL29) was 
then tested in 3D-COL-I cultures, mimicking skin ECM in vivo. As compared to pure COL-I, 
both TN-C and FN, especially when combined, stimulated the infiltrative growth of these 
melanoma cells in COL-I matrix (III: Supplementary Fig. 3), suggesting that they have a 
functional role in melanoma cell migration. 
 
Taken together, our study on TN-C and FN shows these ECM molecules, secreted by 
melanoma cells, to form fibrillar/tubular structures, together with newly synthesized COL-I 
(secreted by nearby fibroblasts), around the invading melanoma cells and to induce the 
migration/invasion of melanoma cells. By secreting these adhesion-related molecules (FN 
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acting as an adhesive protein and TN-C as an anti-adhesive one), melanoma cells presumably 
are able to modify the microenvironment in a direction more permissive for migration and 
invasion promoting contacts (strong enough, but not too strong). The co-localization of 
PCOL-I, secreted by stromal fibroblasts, in the invasion-associated structures formed by 
tumor produced TN-C and FN, further emphasizes the role of tumor microenvironment in 
cancer spreading. According to our observations, both TN-C and FN, as well as some other, 
yet unidentified components of the invasion-related structures, could be potential target 
molecules in cancer therapy. In addition, TN-C further shows prognostic potential, as its 
staining intensity in primary melanoma tumors was found to correlate with metastasis to 
sentinel lymph nodes, better than the Breslow score of tumor thickness routinely used for 
melanoma grading and assessment of metastasis risk. 
 
 
 
2.4 Transforming growth factor beta-induced (IV) 
TGFBI is a transforming growth factor β (TGF-β)-inducible ECM protein which has been 
shown to interact with several other ECM components and various cell surface integrins, and 
thought to function as a linker between these ECM molecules and the integrin receptors (see 
the section “Extracellular matrix molecules”). Interestingly, overexpression of TGFBI has 
been reported in several malignant human tumors, including colorectal, lung, pancreatic, and 
kidney cancers, glioblastoma, neuroblastoma, and aggressive sarcomatoid 
cholangiocarcinoma (Zhang et al. 1997; Kitahara et al. 2001; Buckhaults et al. 2001; Sasaki 
et al. 2002; Schneider et al. 2002; Becker et al. 2006; Tso et al. 2006; Ivanov et al. 2008; Ma 
et al. 2008; Yoo et al. 2009). In functional studies, increased expression of TGFBI has been 
shown to promote invasion and metastatic spread of colon cancer and hepatoma cells (Tang 
et al. 2007; Ma et al. 2008). As we found TGFBI expression to show the second highest up-
regulation in metastatic WM239 cells, we decided to study the role and mechanism of this 
interesting, less studied molecule in melanoma progression. 
 
 
2.4.1 TGFBI is up-regulated in WM793 and WM239 melanoma cells 
The overexpression of TGFBI in WM793 and WM239 melanoma cells was confirmed by 
RT-PCR (IV: Fig. 1A). Further, the metastatic WM239 cells were shown to secrete high 
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levels of TGFBI protein (IV: Fig. 1B). In addition, both the studied melanoma cells were 
found to express the TGFBI’s inducers TGF-β1 and TGF-β2 (IV: Fig. 1A), and also showed 
up-regulated expression of an additional inducer, interleukin 1β (Nam et al. 2006; 5.8- and 
10.9-fold changes, respectively, with Affymetrix arrays). 
 
 
2.4.2 TGFBI is an anti-adhesive protein for melanoma cells and skin fibroblasts 
Due to its FAS domains and RGD motif, TGFBI has been thought to function as a cell 
adhesion molecule. However, TGFBI has been shown to both promote and inhibit cell 
adhesion, probably depending on cell type and the surface molecules expressed. To test the 
effect of TGFBI on melanoma cell adhesion, we coated cell culture wells with different 
known cell adhesive proteins: pFN, cFN, COL-I, LN, VN, as well as recombinant human 
TGFBI, and counted the percentage of bound and spread cells. In these adhesion assays, 
TGFBI was found to be anti-adhesive for melanoma cells, and also adult skin fibroblasts, 
inducing even less cell spreading than the negative control BSA (IV: Fig. 2 and Supplemental 
Fig. 1). Further, when TGFBI was combined 1:1 with the indicated adhesive proteins, it 
substantially weakened melanoma and fibroblast cell adhesion to these molecules (except for 
VN, where only a minor effect was seen) (IV: Fig. 3). To our knowledge, there exist no 
report on interaction of TGFBI and VN, whereas all the other tested molecules have been 
reported to bind to TGFBI, which could explain the different result obtained with VN. 
 
 
2.4.3 TGFBI knockdown stimulates the migration and invasion of melanoma 
cells in vitro 
To study the function of overexpressed TGFBI in melanoma cells, we knocked down its 
expression in WM239 cells using TGFBI short hairpin RNA (shRNA) expression (IV: Fig. 
4A and Supplemental Fig. 2). The resulting WM239 TGFBI knockdown (TGFBI-KD) clones 
showed increased migration in COL-I-coated Boyden chambers (IV: Supplementary Fig. 3), 
as well as in 3D-COL-I gels (IV: Fig. 4B). Similarly, when cultured in 3D-Matrigel matrix, 
the TGFBI-KD cells formed larger invasive colonies than the control cells (IV: Fig. 4C). 
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2.4.4 TGFBI-KD cells show highly concentrated actin filaments co-localizing 
with activated ITGβ1 in pseudopodia-like structures 
As the cytoskeleton plays an important role in cell adhesion and migration, we 
immunostained TGFBI-KD cells for α- and β-tubulins, and F-actin. Interestingly, the TGFBI-
KD cells were found to show highly concentrated actin filaments in pseudopodia-like 
structures, not detected in control cells (IV: Fig. 5). Previously, we had seen similar 
pseudopodia-like structures at the edges of the highly migratory Amdc-s, Amdc-as, and E4 
murine fibrosarcoma cells (Amdc-s and E4 cells shown in Fig. 3). In further studies, ITGβ1 
and talin immunostainings were found to co-localize in these areas, indicating integrin 
activation (IV: Fig. 5 e-f and g-h). TGFBI might thus achieve its anti-adhesive function by 
preventing ITGβ1 activation. By RT-PCR, ITGβ1 and talin mRNA levels were not found to 
be changed in TGFBI-KD cells, but the cells were found to show markedly reduced 
expression of the actin monomer sequestering protein Tβ4 (IV: Fig. 6). 
 
 
2.4.5 TGFBI-KD cells show remarkably impaired tumor growth in nude mice 
To study the effect of TGFBI knockdown on melanoma cell tumorigenicity in vivo, we 
injected TGFBI-KD cells (3 x 106 cells suspended in Matrigel) subcutaneously into nude 
mice. In this experiment, the TGFBI-KD cells were clearly less tumorigenic than the non-
target shRNA expressing control cells (IV: Fig. 7A and Supplemental Fig. 4), implying an 
important role for TGFBI in the growth of these melanoma cells in the complex environment 
in vivo. Bearing in mind the multiple interaction partners of TGFBI, the opposite results 
between the simple and shorter in vitro assays and the complex environment in vivo are 
conceivable. No such good model system exists that could in vitro fully mimic the versatile 
microenvironment the tumors encounter in vivo. 
 
Interestingly, the TGFBI-overexpressing control tumors showed intense TGFBI 
immunostaining at the edges of the infiltrating tumors, invasion fronts (IV: Fig. 7B a and c), 
forming similar fibrillar structures around the melanoma cells that we found previously with 
TN-C, FN, and PCOL-I immunostainings of clinical specimens. Indeed, TGFBI was found to 
show partial co-localization with FN, its interaction partner, in these structures (IV: Fig. 7B 
a-d). In TGFBI-KD cell-induced tumors, only faint TGFBI staining was detected at some 
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areas of the tumor center (IV: Fig. 7B e and data not shown) and the tumors were not able to 
grow. Of special interest, the TGFBI-KD cell-induced tumors showed amorphous, non-
fibrillar pattern of FN staining (IV: Fig. 7B f), implicating that TGFBI may be important for 
the formation of FN fibrils (an integrin-dependent process), which, in turn, may be important 
for the assembly of the invasion-associated structures. 
 
Our studies on the effects of TGFBI on melanoma cell growth in mice identify this ECM 
protein, secreted by metastatic melanoma cells, to clearly contribute to the progression of 
melanoma tumors and to show potential for cancer therapy. Interestingly, periostin (POSTN), 
an anti-adhesive protein showing a highly similar structure to TGFBI, has been recently 
found to co-localize with FN and COL-I in the fibrillar networks in melanoma metastases 
(Soikkeli et al. 2010). As FN, COL-I, TGFBI, and POSTN all are TGF-β-inducible proteins, 
TGF-β receptors might also be effectively exploited as therapy target to control melanoma 
progression. 
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CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
 
In our fibrosarcoma study, we found two new, interesting up-regulated molecules relevant for 
fibrosarcoma cell invasion, an actin sequestering protein thymosin β4 (Tβ4) and a cell 
adhesion receptor integrin α6 (ITGα6) that was complexed with integrin β1 (ITGβ1). Based 
on the presented and previous data, we propose the possibility of using a combination therapy 
consisting of ITGα6β1 antagonists (affecting tumor cell adhesion), Tβ4 inhibitors (affecting 
tumor cell migration), and cathepsin L inhibitors (affecting the degradation of ECM/BM 
proteins) for the treatment of fibrosarcomas and other sarcomas/tumors overexpressing these 
molecules. This kind of combinatory therapy could be more effective than therapies 
exploiting only one feature of cancer cells, as the development of resistance should be slower. 
 
In the other part of this work, melanoma study, we found the extracellular matrix proteins 
tenascin-C (TN-C), fibronectin (FN), and transforming growth factor beta-induced (TGFBI) 
to be highly expressed and secreted by invasive melanoma cells. As all these molecules 
function in cell adhesion and showed co-localization in melanoma tissues, we propose that 
melanoma cells secrete these molecules to modify their microenvironment to become more 
supportive for their adhesive interactions and, in that way, their migration and spreading. In 
addition, these molecules may be important for the regulation of growth and apoptosis of 
melanoma and other cells. Our results on TN-C, FN, and TGFBI, as well as the stromal 
fibroblast secreted protein collagen-I, thus strengthen the view of the importance of tumor 
microenvironment on the aggressiveness of human tumors and identify these molecules as 
potential melanoma biomarkers or therapeutic targets. In the future, the promising potentials 
of TN-C, especially the large splice variants, as a melanoma prognostic marker and the 
knockdown or inhibition of TGFBI as a melanoma treatment strategy should be studied 
further. 
 
In this study, we managed to find several candidate molecules and characterized in more 
detail six molecules showing most promising for cancer diagnostics or prognostics, or 
therapeutic targets. The fact that the identified molecules represent both tumor cell-specific 
and ECM-related molecules (produced also by stromal cells) emphasizes the importance of 
not only tumor cells but also the tumor microenvironment in tumor dissemination. Most 
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potent therapeutic approaches are, therefore, likely to target multiple features of this complex 
process. 
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